Characteristics of Drug-Induced Urticaria Based on Data of the Allergology and Immunology Department of the Mordovia Republic Clinical Hospital

Authors: Цапленкова, Анастасия Евгеньев, orcid:0009-0009-5952-, Дьячкова, Анна Альбертовна

Subject Terms: лекарственная крапивница, аллергология, антибиотики, нестероидные противовоспалительные средства, ингибиторы ангиотензинпревращающего фермента, сартаны

Relation: https://zenodo.org/records/15275589; oai:zenodo.org:15275589

Availability: https://doi.org/10.15507/2311-2468.013.202501.081-087
https://zenodo.org/records/15275589

Toxic reactions of non-steroidal anti-inflammatory drugs in the Russian Federation, analysis of the national database 'Pharmacovigilance'

Authors: G. I. Syraeva, V. B. Vasilyuk, A. V. Verveda, M. V. Faraponova, A. S. Kolbin, V. G. Borovskaya

Source: Качественная клиническая практика, Vol 0, Iss 4, Pp 73-82 (2023)

Subject Terms: фармаконадзор, RS1-441, нежелательные реакции, Pharmacy and materia medica, Medical technology, нестероидные противовоспалительные средства, лекарственное поражение печени, аис рзн, R855-855.5, 3. Good health

Access URL: https://doaj.org/article/c797d8c511354299bee6ed341b27f170

Quantitative and qualitative evaluation of the use of nonsteroidal anti-inflammatory drugs in the Russian Federation over 10 years

Authors: G. I. Syraeva, A. S. Kolbin, S. A. Mishinova, A. A. Kalyapin

Source: Качественная клиническая практика, Vol 0, Iss 3, Pp 19-30 (2022)

Subject Terms: фармаконадзор, RS1-441, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, фармакоэкономика, Medical technology, нестероидные противовоспалительные средства, нежелательные лекарственные реакции, R855-855.5, автоматизированная информационная система росздравнадзора, ddd, 3. Good health

Access URL: https://doaj.org/article/2251cd55ff8e47c8b9cf01c40c9905d3

Nonsteroidal anti-inflammatory drugs’ adverse drug reactions: 10 years of national database data

Authors: G. I. Syraeva, A. S. Kolbin

Source: Качественная клиническая практика, Vol 0, Iss 4, Pp 16-26 (2022)

Subject Terms: фармаконадзор, RS1-441, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, Medical technology, нестероидные противовоспалительные средства, нежелательные лекарственные реакции, R855-855.5, автоматизированная информационная система росздравнадзора, 3. Good health

Access URL: https://www.clinvest.ru/jour/article/download/593/602
https://doaj.org/article/ce606c7316234f649f71ce8001d988ab

Erector Spinae Plane block: evaluation of its efficacy as a component of multimodal anaesthesia in open kidney surgery ; Оценка эффективности блокады мышцы, выпрямляющей спину [Erector Spinae Plane block], как компонента мультимодальной анестезии при открытых операциях на почках

Authors: P. M. Kayumova, Sh. I. Giyasov, M. B. Krasnenkova, A. N. Musabaev, П. М. Каюмова, Ш. И. Гиясов, М. Б. Красненкова, А. Н. Мусабаев

Source: Urology Herald; Том 12, № 1 (2024); 36-44 ; Вестник урологии; Том 12, № 1 (2024); 36-44 ; 2308-6424 ; 10.21886/2308-6424-2024-12-1

Subject Terms: лечение боли, anti-inflammatory agents, non-steroidal, Erector Spinae Plane (ESP) block, nephrectomy, postoperative pain, pain management, нестероидные противовоспалительные средства, блокады мышцы, выпрямляющей спину / Erector Spinae Plane (ESP) block, нефрэктомия, послеоперационная боль

File Description: application/pdf

Relation: https://www.urovest.ru/jour/article/view/828/532; Акилов Ф.А., Гиясов Ш.И. Анализ причин, частоты и тяжести острого осложнённого пиелонефрита при эндоскопической хирургии уролитиаза. Вестник урологии. 2017;5(4):5-12. DOI:10.21886/2308-6424-2017-5-4-5-12; Мирзамухамедов А.Г., Каримов Ш.И, Азизов С.З. Оперативные доступы к органам забрюшинного пространства. Монография. Ташкент; 1994.; Mayor G, Zingg EJ: Urologische Operationen, Atlas zur Indikation Technik und Nachbehandlung. Stuttgart: Thieme; 1973.; Gerbershagen HJ, Aduckathil S, van Wijck AJ, Peelen LM, Kalkman CJ, Meissner W. Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures. Anesthesiology. 2013;118(4):934-44. DOI:10.1097/ALN.0b013e31828866b3; Овечкин А.М., Баялиева А.Ж., Ежевская А.А., Еременко А.А., Заболотский Д.В., Заболотских И., Карелов А.Е., Корячкин В.А., Спасова А.П., Хороненко В.Э., Уваров Д.Н., Ульрих Г.Э., Шадрин Р.В. Послеоперационное обезболивание. Клинические рекомендации. Вестник интенсивной терапии имени А.И. Салтанова. 2019;(4):9-33. DOI:10.21320/1818-474X-2019-4-9-33; Gautam SKS, Das PK, Agarwal A, Kumar S, Dhiraaj S, Keshari A, Patro A. Comparative Evaluation of Continuous Thoracic Paravertebral Block and Thoracic Epidural Analgesia Techniques for Post-operative Pain Relief in Patients Undergoing Open Nephrectomy: A Prospective, Randomized, Single-blind Study. Anesth Essays Res. 2017;11(2):359-364. DOI:10.4103/0259-1162.194559; Forero M, Adhikary SD, Lopez H, Tsui C, Chin KJ. The Erector Spinae Plane Block: A Novel Analgesic Technique in Thoracic Neuropathic Pain. Reg Anesth Pain Med. 2016;41(5):621-627. DOI:10.1097/AAP.0000000000000451; Taketa Y, Irisawa Y, Fujitani T. Ultrasound-guided erector spinae plane block elicits sensory loss around the lateral, but not the parasternal, portion of the thorax. J Clin Anesth. 2018;47:84-85. DOI:10.1016/j.jclinane.2018.03.023; Taketa Y, Irisawa Y, Fujitani T. Comparison of ultrasoundguided erector spinae plane block and thoracic paravertebral block for postoperative analgesia after video-assisted thoracic surgery: a randomized controlled non-inferiority clinical trial. Reg Anesth Pain Med. 2019:rapm-2019-100827. DOI:10.1136/rapm-2019-100827. Epub ahead of print; Nagaraja PS, Ragavendran S, Singh NG, Asai O, Bhavya G, Manjunath N, Rajesh K. Comparison of continuous thoracic epidural analgesia with bilateral erector spinae plane block for perioperative pain management in cardiac surgery. Ann Card Anaesth. 2018;21(3):323-327. DOI:10.4103/aca.ACA_16_18; Celik M, Tulgar S, Ahiskalioglu A, Alper F. Is high volume lumbar erector spinae plane block an alternative to transforaminal epidural injection? Evaluation with MRI. Reg Anesth Pain Med. 2019:rapm-2019-100514. DOI:10.1136/rapm-2019-100514; Tulgar S, Kose HC, Selvi O, Senturk O, Thomas DT, Ermis MN, Ozer Z. Comparison of Ultrasound-Guided Lumbar Erector Spinae Plane Block and Transmuscular Quadratus Lumborum Block for Postoperative Analgesia in Hip and Proximal Femur Surgery: A Prospective Randomized Feasibility Study. Anesth Essays Res. 2018;12(4):825-831. DOI:10.4103/aer.AER_142_18; Aksu C, Şen MC, Akay MA, Baydemir C, Gürkan Y. Erector Spinae Plane Block vs Quadratus Lumborum Block for pediatric lower abdominal surgery: A double blinded, prospective, and randomized trial. J Clin Anesth. 2019;57:24-28. DOI:10.1016/j.jclinane.2019.03.006; Canturk M. Lumbar erector spinae plane block for postoperative analgesia after nephrectomy followed by emergent complication surgery. Minerva Anestesiol. 2019;85(9):1032-1033. DOI:10.23736/S0375-9393.19.13663-2; Elsharkawy H, El-Boghdadly K, Barrington M. Quadratus Lumborum Block: Anatomical Concepts, Mechanisms, and Techniques. Anesthesiology. 2019;130(2):322-335. DOI:10.1097/ALN.0000000000002524; Şahin A, Baran O. Effect of ultrasound-guided erector spinae plane block on post-surgical pain in patients undergoing nephrectomy: a single-center, randomized, double-blind, controlled trial. J Int Med Res. 2022;50(3):3000605221086737. DOI:10.1177/03000605221086737; Aksu C, Gürkan Y. Ultrasound guided erector spinae block for postoperative analgesia in pediatric nephrectomy surgeries. J Clin Anesth. 2018;45:35-36. DOI:10.1016/j.jclinane.2017.12.021; Onay M, Erdoğan Kayhan G, Özen A, Şanal Baş S, Yelken B. Comparison of ultrasound-guided quadratus lumborum block and erector spinae plane block in terms of their effects on postoperative pain in open nephrectomy. Minerva Anestesiol. 2023;89(1-2):32-39. DOI:10.23736/S0375-9393.22.16635-6; Sullivan TR, Kanda P, Gagne S, Costache I. Harlequin Syndrome Associated with Erector Spinae Plane Block. Anesthesiology. 2019;131(3):665. DOI:10.1097/ALN.0000000000002733; Elkoundi A, Eloukkal Z, Bensghir M, Belyamani L. Priapism following erector spinae plane block for the treatment of a complex regional pain syndrome. Am J Emerg Med. 2019;37(4):796.e3-796.e4. DOI:10.1016/j.ajem.2019.01.012; Selvi O, Tulgar S. Ultrasound guided erector spinae plane block as a cause of unintended motor block. Rev Esp Anestesiol Reanim (Engl Ed). 2018;65(10):589-592. (In English, Spanish). DOI:10.1016/j.redar.2018.05.009; Tulgar S, Selvi O, Senturk O, Serifsoy TE, Thomas DT. Ultrasound-guided Erector Spinae Plane Block: Indications, Complications, and Effects on Acute and Chronic Pain Based on a Single-center Experience. Cureus. 2019;11(1):e3815. DOI:10.7759/cureus.3815; Maddineni U, Maarouf R, Johnson C, Fernandez L, Kazior MR. Safe and Effective Use of Bilateral Erector Spinae Block in Patient Suffering from Post-Operative Coagulopathy Following Hepatectomy. Am J Case Rep. 2020;21:e921123. DOI:10.12659/AJCR.921123; Galacho J, Veiga M, Ormonde L. Erector spinae plane block and altered hemostasis: is it a safe option? -a case series. Korean J Anesthesiol. 2020;73(5):445-449. DOI:10.4097/kja.20078; https://www.urovest.ru/jour/article/view/828

Availability: https://www.urovest.ru/jour/article/view/828
https://doi.org/10.21886/2308-6424-2024-12-1-36-44

Analysis of the Consumption of Medicinal Products Associated with a High Risk of Drug-Induced Liver Injury in Patients with COVID-19 ; Анализ потребления препаратов с высоким риском развития лекарственного поражения печени при COVID-19

Authors: V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva, В. И. Петров, А. Ю. Рязанова, Н. С. Токарева

Contributors: The study was performed without external funding., Работа выполнена без спонсорской поддержки.

Source: Safety and Risk of Pharmacotherapy; Том 12, № 3 (2024); 268-284 ; Безопасность и риск фармакотерапии; Том 12, № 3 (2024); 268-284 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2024-12-3

Subject Terms: АТС/DDD-анализ, drug-induced liver injury, COVID-19, alanine transaminase, hepatotoxicity, adverse drug reactions, antimicrobials, NSAIDs, omeprazole, favipiravir, remdesivir, ATC/DDD analysis, лекарственные поражения печени, аланиновая трансаминаза, гепатотоксичность, нежелательные реакции, антибактериальные препараты, нестероидные противовоспалительные средства, омепразол, фавипиравир, ремдесивир

File Description: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/396/1221; https://www.risksafety.ru/jour/article/view/396/1047; https://www.risksafety.ru/jour/article/view/396/1049; https://www.risksafety.ru/jour/article/view/396/1053; https://www.risksafety.ru/jour/article/view/396/1056; https://www.risksafety.ru/jour/article/view/396/1064; https://www.risksafety.ru/jour/article/view/396/1061; https://www.risksafety.ru/jour/article/view/396/1070; https://www.risksafety.ru/jour/article/view/396/1071; https://www.risksafety.ru/jour/article/view/396/1086; https://www.risksafety.ru/jour/article/view/396/1090; https://www.risksafety.ru/jour/article/downloadSuppFile/396/475; https://www.risksafety.ru/jour/article/downloadSuppFile/396/481; https://www.risksafety.ru/jour/article/downloadSuppFile/396/483; Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver Int. 2020;40(6):1321–6. https://doi.org/10.1111/liv.14449; Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol. 2020;18(7):1561–6. https://doi.org/10.1016/j.cgh.2020.04.002; Yadav DK, Singh A, Zhang Q, Bai X, Zhang W, Yadav RK, et al. Involvement of liver in COVID-19: systematic review and meta-analysis. Gut. 2021;70(4):807–9. https://doi.org/10.1136/gutjnl-2020-322072; Pazgan-Simon M, Serafińska S, Kukla M, Kucharska M, Zuwała-Jagiełło J, Buczyńska I, et al. Liver injury in patients with COVID-19 without underlying liver disease. J Clin Med. 2022;11(2):308. https://doi.org/10.3390/jcm11020308; Olry A, Meunier L, Délire B, Larrey D, Horsmans Y, Le Louët H. Drug-induced liver injury and COVID-19 infection: the rules remain the same. Drug Saf. 2020;43(7):615–17. https://doi.org/10.1007/s40264-020-00954-z; Sodeifian F, Seyedalhosseini ZS, Kian N, Eftekhari M, Najari S, Mirsaeidi M, et al. Drug-induced liver injury in COVID-19 patients: a systematic review. Front Med (Lausanne). 2021;8:731436. https://doi.org/10.3389/fmed.2021.731436; Ивашкин ВТ, Барановский АЮ, Райхельсон КЛ, Пальгова ЛК, Маевская МВ, Кондрашина ЭА и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):101–31. https://doi.org/10.22416/1382-4376-2019-29-1-101-131; Цветов ВМ, Бурашникова ИС, Сычев ДА, Поддубная ИВ. Возможность и перспективы применения препаратов из группы цитостатиков у пациентов с COVID-19 на примере циклофосфамида. Фарматека. 2021;28(1):10–3. https://doi.org/10.18565/pharmateca.2021.1.10-13; Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015;89(3):327–34. https://doi.org/10.1007/s00204-015-1456-2; Буеверов АО, Богомолов ПО, Буеверова ЕЛ. Гепатотоксичность антибактериальных препаратов в терапевтической практике. Клиническая микробиология и антимикробная химиотерапия. 2015;17(3):207–16. EDN: UHPUXJ; deLemos AS, Ghabril M, Rockey DC, Gu J, Barnhart HX, Fontana RJ, et al. Amoxicillin-clavulanate-induced liver injury. Dig Dis Sci. 2016;61(8):2406–16. https://doi.org/10.1007/s10620-016-4121-6; Katarey D, Verma S. Drug-induced liver injury. Clin Med (Lond). 2016;16(Suppl. 6):s104-s109. https://doi.org/10.7861/clinmedicine.16-6-s104; Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99. https://doi.org/10.1056/NEJMoa2001282; Fontana RJ, Hayashi P, Bonkovsky HL, Kleiner DE, Kochhar S, Gu J, Ghabril M. Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig Dis Sci. 2013;58(6):1766–75. https://doi.org/10.1007/s10620-012-2553-1; Tsuzuki S, Hayakawa K, Dоi Y, Shinozaki T, Uemura Y, Matsunaga N, et al. Effectiveness of favipiravir on nonsevere, early-stage COVID-19 in Japan: a large observational study using the COVID-19 Registry Japan. Infect Dis Ther. 2022;11(3):1075–87. https://doi.org/10.1007/s40121-022-00617-9; Руженцова ТА, Чухляев ПВ, Хавкина ДА, Гарбузов АА, Плоскирева АА, Осешнюк РА и др. Эффективность и безопасность применения фавипиравира в комплексной терапии COVID-19 легкого и среднетяжелого течения. Инфекционные болезни: новости, мнения, обучение. 2020;9(4):26–38. https://doi.org/10.33029/2305-3496-2020-9-4-26-38; Bjork JA, Wallace KB. Remdesivir; molecular and functional measures of mitochondrial safety. Toxicol Appl Pharmacol. 2021;433:115783. https://doi.org/10.1016/j.taap.2021.115783; Петров ВИ, Рязанова АЮ, Привальцева НС, Некрасов ДА. Опыт применения ремдесивира для лечения новой коронавирусной инфекции. Безопасность и риск фармакотерапии. 2022;10(4):365–80. https://doi.org/10.30895/2312-7821-2022-10-4-365-380; Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(5):849–58. https://doi.org/10.1093/rheumatology/key361; Serviddio G, Villani R, Stallone G, Scioscia G, Foschino-Barbaro MP, Lacedonia D. Tocilizumab and liver injury in patients with COVID-19. Therap Adv Gastroenterol. 2020;13:1756284820959183. https://doi.org/10.1177/1756284820959183; Ortiz GX, Lenhart G, Becker MW, Schwambach KH, Tovo CV, Blatt CR. Drug-induced liver injury and COVID-19: a review for clinical practice. World J Hepatol. 2021;13(9):1143–53. https://doi.org/10.4254/wjh.v13.i9.1143; Jorgensen SCJ, Tse CLY, Burry L, Dresser LD. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy. 2020;40(8):843–56. https://doi.org/10.1002/phar.2438; Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of nonsteroidal anti-inflammatory drugs: a systematic review of randomized controlled trials. Int J Hepatol. 2018;2018:5253623. https://doi.org/10.1155/2018/5253623; Schrör K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs. 2007;9(3):195–204. https://doi.org/10.2165/00148581-200709030-00008; Dart RC, Erdman AR, Olson KR, Christianson G, Manoguerra AS, Chyka PA, et al. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2006;44(1):1–18. https://doi.org/10.1080/15563650500394571; Park BK, Dear JW, Antoine DJ. Paracetamol (acetaminophen) poisoning. BMJ Clin Evid. 2015;2015:2101. PMID: 26479248; Tsuda T, Tada H, Tanaka Y, Nishida N, Yoshida T, Sawada T, et al. Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports. J Med Case Rep. 2018;12(1):95. https://doi.org/10.1186/s13256-018-1629-8; Babatin M, Lee SS, Pollak PT. Amiodarone hepatotoxicity. Curr Vasc Pharmacol. 2008;6(3):228–36. https://doi.org/10.2174/157016108784912019; Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol. 2003;15(8):921–4. https://doi.org/10.1097/00042737-200308000-00014; https://www.risksafety.ru/jour/article/view/396

Availability: https://www.risksafety.ru/jour/article/view/396
https://doi.org/10.30895/2312-7821-2024-396

ТЕРАПЕВТИЧЕСКАЯ ТАКТИКА ПРИ АНОМАЛЬНЫХ МАТОЧНЫХ КРОВОТЕЧЕНИЯХ, НЕ СВЯЗАННЫХ СО СТРУКТУРНЫМИ АНОМАЛИЯМИ МАТКИ

Subject Terms: аномальные маточные кровотечения, левоноргестрел-содержащая внутриматочная система, эстрадиола валерат, диеногест, гестагены, нестероидные противовоспалительные средства, транексамовая кислота

ТЕРАПЕВТИЧЕСКАЯ ТАКТИКА ПРИ АНОМАЛЬНЫХ МАТОЧНЫХ КРОВОТЕЧЕНИЯХ, НЕ СВЯЗАННЫХ СО СТРУКТУРНЫМИ АНОМАЛИЯМИ МАТКИ

Subject Terms: аномальные маточные кровотечения, левоноргестрел-содержащая внутриматочная система, эстрадиола валерат, диеногест, гестагены, нестероидные противовоспалительные средства, транексамовая кислота

Современные концепции возникновения боли и возможности ее преодоления в общей врачебной практике

Authors: R.V. Svistilnik

Source: INTERNATIONAL NEUROLOGICAL JOURNAL; Том 16, № 7 (2020); 61-69
МЕЖДУНАРОДНЫЙ НЕВРОЛОГИЧЕСКИЙ ЖУРНАЛ; Том 16, № 7 (2020); 61-69
МІЖНАРОДНИЙ НЕВРОЛОГІЧНИЙ ЖУРНАЛ; Том 16, № 7 (2020); 61-69

Subject Terms: болевой синдром, нестероидные противовоспалительные средства, лечение, больовий синдром, нестероїдні протизапальні засоби, лікування, pain syndrome, non-steroidal anti-inflammatory drugs, treatment, 3. Good health

File Description: application/pdf

Access URL: http://inj.zaslavsky.com.ua/article/view/218249

Нестероидные противовоспалительные средства: современное представление о механизмах повреждения пищеварительного тракта, минусы препаратов патогенетического лечения и перспективы биологической терапии НПВС-индуцированной эзофагогастроэнтероколонопатии

Authors: F.V. Hladkykh, M.O. Chyzh

Source: GASTROENTEROLOGY; Том 54, № 4 (2020); 253-266
Гастроэнтерология-Gastroenterologìa; Том 54, № 4 (2020); 253-266
Гастроентерологія-Gastroenterologìa; Том 54, № 4 (2020); 253-266

Subject Terms: 0301 basic medicine, 0303 health sciences, 03 medical and health sciences, 0302 clinical medicine, нестероїдні протизапальні засоби, ульцерогенність, езофагогастроентероколонопатія, кріоконсервований екстракт плаценти, nonsteroidal anti-inflammatory drugs, ulcerogenicity, esophagogastroenterocolonopathy, cryopreserved placental extract, нестероидные противовоспалительные средства, ульцерогенность, эзофагогастроэнтероколонопатия, криоконсервированный экстракт плаценты, 3. Good health

File Description: application/pdf

Access URL: http://gastro.zaslavsky.com.ua/article/download/216714/220511
http://gastro.zaslavsky.com.ua/article/view/216714
http://gastro.zaslavsky.com.ua/article/view/216714

Oshqozon va o'n ikki barmoqli ichak yara kasalligiga chalingan bemorlarni davolashning umumiy tamoyillari va profilaktikasi

Authors: O`G`Li, Toshpo`Latov Sardorjon Sarvar, O`G`Li, Azimov Jurabek Shavkatjon

Subject Terms: Helicobacter pylori, 'MAASTRIX IV-V KONSENSUS', ezofagogastroduodenoskopiya, rentgenoskopiya, НПВС-нестероидные противовоспалительные средства

Nonsteroidal Anti-Inflammatory Drugs: Risks and Benefits

Source: Неврология и нейрохирургия. Восточная Европа. :414-434

Subject Terms: 0301 basic medicine, cyclo- oxygenase, nonsteroidal anti-inflammatory drugs, NSAID-gastropathy, циклооксигеназа, нестероидные противовоспалительные средства, НПВС- гастропатия, CYP2C9 polymorphism, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, inflammation, селективные ингибиторы ЦОГ, полиморфизм CYP2C9, selective COX inhibitors, воспаление

Treatment optimization of patients with Helicobacter pylori-associated NSAID gastropathy, combined with ischemic heart disease

Authors: Skrypnyk, I. M., Parkhomenko, V. V., Gopko, O. F.

Source: Современная гастроэнтерология; № 2 (2020); 24—29
Сучасна гастроентерологія; № 2 (2020); 24—29
Modern Gastroenterology; № 2 (2020); 24—29

Subject Terms: nonsteroidal anti‑inflammatory drugs, ischemic heart disease, NSAID gastropathy, eupatilin, Stilen, cytoprotection, нестероидные противовоспалительные средства, ишемическая болезнь сердца, НПВС‑гастропатия, эупатилин, «Стилен», цитопротекция, нестероїдні протизапальні засоби, ішемічна хвороба серця, НПЗЗ‑гастропатія, еупатилін, цитопротекція, 3. Good health

File Description: application/pdf

Access URL: http://sgastro.com.ua/article/view/MG-2020-2-24

Treatment of acute and chronic cervical musculoskeletal pain ; Лечение острой и хронической шейной скелетно-мышечной боли

Authors: A. I. Isaikin, A. Kh. Mukhametzyanova, L. T. Akhmedzhanova, A. S. Romanova, А. И. Исайкин, А. Х. Мухаметзянова, Л. Т. Ахмеджанова, А. С. Романова

Source: Meditsinskiy sovet = Medical Council; № 10 (2023); 55–62 ; Медицинский Совет; № 10 (2023); 55–62 ; 2658-5790 ; 2079-701X

Subject Terms: современные классификации боли в шее, chronic musculoskeletal neck pain, risk factors, NSAIDs, modern classifications of neck pain, хроническая скелетно-мышечная боль в шее, факторы риска, нестероидные противовоспалительные средства

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7641/6774; Guzman J., Hurwitz E.L., Carroll L.J., Haldeman S., Côté P., Carragee E.J. et al. A new conceptual model of neck pain: linking onset, course, and care: the Bone and Joint Decade 2000–2010 Task Force on Neck Pain and Its Associated Disorders. Spine (Phila Pa 1976). 2008;33(Suppl. 4):S14–23. https://doi.org/10.1097/brs.0b013e3181643efb.; Safiri S., Kolahi A.A., Hoy D., Buchbinder R., Mansournia M.A., Bettampadi D. et al. Global, regional, and national burden of neck pain in the general population, 1990–2017: systematic analysis of the Global Burden of Disease Study 2017. BMJ. 2020;368:m791. https://doi.org/10.1136/bmj.m791.; Dieleman J.L., Cao J., Chapin A., Chen C., Li Z., Liu A. et al. US Health Care Spending by Payer and Health Condition, 1996–2016. JAMA. 2020;323(9):863–884. https://doi.org/10.1001/jama.2020.0734.; Domingues L., Cruz E.B., Pimentel- Santos F.M., Ramiro S., Donato H., Manica S.R. et al. Prognostic factors for recovery and non-recovery in patients with non-specific neck pain: a protocol for a systematic literature review. BMJ Open. 2018;8(11):e023356. https://doi.org/10.1136/bmjopen-2018-023356.; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100): 1211–1259. https://doi.org/10.1016/S0140-6736(17)32154-2.; Kim R., Wiest C., Clark K., Cook C., Horn M. Identifying risk factors for first- episode neck pain: A systematic review. Musculoskelet Sci Pract. 2018;33:77–83. https://doi.org/10.1016/j.msksp.2017.11.007.; McLean S.M., May S., Klaber- Moffett J., Sharp D.M., Gardiner E. Risk factors for the onset of non-specific neck pain: a systematic review. J Epidemiol Community Health. 2010;64(7):565–572. https://doi.org/10.1136/jech.2009.090720.; Côté P., van der Velde G., Cassidy J.D., Carroll L.J., Hogg- Johnson S., Holm L.W. et al. The burden and determinants of neck pain in workers: results of the Bone and Joint Decade 2000–2010 Task Force on Neck Pain and Its Associated Disorders. Spine (Phila Pa 1976). 2008;33(Suppl. 4):S60–74. https://doi.org/10.1097/BRS.0b013e3181643ee4.; Исайкин А.И., Мисюряева Е.В., Голенкова С.С. Хлыстовая травма. Эффективная фармакотерапия. 2022;18(43):84–89. Режим доступа: https://umedp.ru/articles/khlystovaya_travma.html.; Guzman J., Haldeman S., Carroll L.J., Carragee E.J., Hurwitz E.L., Peloso P. et al. Clinical practice implications of the Bone and Joint Decade 2000–2010 Task Force on Neck Pain and Its Associated Disorders: from concepts and findings to recommendations. Spine (Phila Pa 1976). 2008;33(Suppl. 4): S199–S213. https://doi.org/10.1097/BRS.0b013e3181644641.; Douglass A.B., Bope E.T. Evaluation and treatment of posterior neck pain in family practice. J Am Board Fam Pract. 2004;(Suppl. 17):S13–22. https://doi.org/10.3122/jabfm.17.suppl_1.s13.; Vasseljen O., Woodhouse A., Bjørngaard J.H., Leivseth L. Natural course of acute neck and low back pain in the general population: the HUNT study. Pain. 2013;154(8):1237–1244. https://doi.org/10.1016/j.pain.2013.03.032.; Vos C.J., Verhagen A.P., Passchier J., Koes B.W. Clinical course and prognostic factors in acute neck pain: an inception cohort study in general practice. Pain Med. 2008;9(5):572–580. https://doi.org/10.1111/j.1526-4637.2008.00456.x.; Carstensen T.B. The influence of psychosocial factors on recovery following acute whiplash trauma. Dan Med J. 2012;59(12):B4560. Available at: https://pubmed.ncbi.nlm.nih.gov/23290295/.; Исайкин А.И., Шмидт Т.Е., Шор Ю.М. Цервикальная радикулопатия. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):103–108. https://doi.org/10.14412/2074-2711-2022-5-103-108.; Головачева В.А., Головачева А.А., Парфенов В.А. Ведение пациентов с подострой болью в спине: как эффективно предупредить хронизацию. Неврология, нейропсихиатрия, психосоматика. 2022;14(4):62–67. https://doi.org/10.14412/2074-2711-2022-4-62-67.; Parikh P., Santaguida P., Macdermid J., Gross A., Eshtiaghi A. Comparison of CPG’s for the diagnosis, prognosis and management of non-specific neck pain: a systematic review. BMC Musculoskelet Disord. 2019;20(1):81. https://doi.org/10.1186/s12891-019-2441-3.; Cohen S.P., Huang J.H., Brummett C. Facet joint pain – advances in patient selection and treatment. Nat Rev Rheumatol. 2013;9(2):101–116. https://doi.org/10.1038/nrrheum.2012.198.; Cohen S.P. Epidemiology, diagnosis, and treatment of neck pain. Mayo Clin Proc. 2015;90(2):284–299. https://doi.org/10.1016/j.mayocp.2014.09.008.; Исайкин А.И., Насонова Т.И. Мышечный фактор в развитии скелетно- мышечной боли. Возможности терапии. Неврология, нейропсихиатрия, психосоматика. 2022;14(2):98–104. https://doi.org/10.14412/2074-27112022-2-98-104.; Peng B., Bogduk N. Cervical Discs as a Source of Neck Pain. An Analysis of the Evidence. Pain Med. 2019;20(3):446–455. https://doi.org/10.1093/pm/pny249.; Childs J.D., Cleland J.A., Elliott J.M., Teyhen D.S., Wainner R.S., Whitman J.M. et al. Neck pain: Clinical practice guidelines linked to the International Classification of Functioning, Disability, and Health from the Orthopedic Section of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2008;38(9):A1–A34. https://doi.org/10.2519/jospt.2008.0303.; Исайкин А.И., Акарачкова Е.А., Ахунов А.Н. Диагностика и лечение острой неспецифической боли в шейном отделе у лиц молодого возраста. Эффективная фармакотерапия. 2021;17(29):22–30. Режим доступа: https://umedp.ru/articles/diagnostika_i_lechenie_ostroy_nespetsificheskoy_boli_v_sheynom_otdele_u_lits_molodogo_vozrasta.html.; Lemeunier N., da Silva- Oolup S., Chow N., Southerst D., Carroll L., Wong J.J. et al. Reliability and validity of clinical tests to assess the anatomical integrity of the cervical spine in adults with neck pain and its associated disorders: Part 1 – A systematic review from the Cervical Assessment and Diagnosis Research Evaluation (CADRE) Collaboration. Eur Spine J. 2017;26(9):2225–2241. https://doi.org/10.1007/s00586-017-5153-0.; Côté P., Wong J.J., Sutton D., Shearer H.M., Mior S., Randhawa K. et al. Management of neck pain and associated disorders: A clinical practice guideline from the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration. Eur Spine J. 2016;25(7):2000–2022. https://doi.org/10.1007/s00586-016-4467-7.; Dandale C., Telang P.A., Kasatwar P. The Effectiveness of Ergonomic Training and Therapeutic Exercise in Chronic Neck Pain in Accountants in the Healthcare System: A Review. Cureus. 2023;15(3):e35762. https://doi.org/10.7759/cureus.35762.; Mourad F., Rossettini G., Galeno E., Patuzzo A., Zolla G., Maselli F. et al. Use of Soft Cervical Collar among Whiplash Patients in Two Italian Emergency Departments Is Associated with Persistence of Symptoms: A Propensity Score Matching Analysis. Healthcare (Basel). 2021;9(10):1363. https://doi.org/10.3390/healthcare9101363.; Corp N., Mansell G., Stynes S., Wynne-J ones G., Morsø L., Hill J.C., van der Windt D.A. Evidence- based treatment recommendations for neck and low back pain across Europe: A systematic review of guidelines. Eur J Pain. 2021;25(2):275–295. https://doi.org/10.1002/ejp.1679.; Исайкин А.И., Насонова Т.И., Мухаметзянова А.Х. Эмоциональные нарушения и их терапия при хронической поясничной боли. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):90–95. https://doi.org/10.14412/2074-2711-2022-5-90-95.; Castellini G., Pillastrini P., Vanti C., Bargeri S., Giagio S., Bordignon E. et al. Some conservative interventions are more effective than others for people with chronic non-specific neck pain: a systematic review and network meta-analysis. J Physiother. 2022;68(4):244–254. https://doi.org/10.1016/j.jphys.2022.09.007.; De Zoete R.M., Armfield N.R., McAuley J.H., Chen K., Sterling M. Comparative effectiveness of physical exercise interventions for chronic non-specific neck pain: a systematic review with network meta-analysis of 40 randomised controlled trials. Br J Sports Med. 2021;55(13):730–742. https://doi.org/10.1136/bjsports-2020-102664.; Chou R., Côté P., Randhawa K., Torres P., Yu H., Nordin M. et al. The Global Spine Care Initiative: applying evidence- based guidelines on the non-invasive management of back and neck pain to low- and middle-i ncome communities. Eur Spine J. 2018;27(Suppl. 6):851–860. https://doi.org/10.1007/s00586-017-5433-8.; Головачева В.А., Табеева Г.Р., Фатеева Т.Г. Ведение пациентов со скелетно мышечной болью в спине и коморбидной тревогой. Медицинский совет. 2022;(23):60–66. https://doi.org/10.21518/2079701X-2022-16-23-60-66.; Головачева В.А., Парфенов В.А. Лечение скелетно-мышечных болей в период пандемии COVID- 19. Клиническая фармакология и терапия. 2022;31(1):24–31. Режим доступа: https://clinpharm-journal.ru/articles/2022-1/lechenie-skeletno-myshechnyh-bolej-v-period-pandemii-COVID-19/.; Головачева А.А., Головачева В.А., Парфенов В.А. Кинезиотерапия и нестероидные противовоспалительные препараты при неспецифической люмбалгии. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):89–96. https://doi.org/10.14412/2074-2711-2022-1-89-96.; Рожков Д.О., Шевцова К.В., Гринюк В.В., Парфенов В.А. Результаты клинического неинтервенционного исследования ЭЛЬБРУС. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):49–54. https://doi.org/10.14412/2074-2711-2022-5-49-54.; Соловьева Э.Ю., Карнеев А.Н., Федин А.И. Сочетанное применение дексалгина и нимесила в стадии обострения дорсопатии. Врач. 2007;(3):67–71. Режим доступа: https://elibrary.ru/item.asp?id=12974322.; Соловьева Э.Ю., Карнеев А.Н., Иваноков А.Н., Джутова Э.Д. Декскетопрофен в лечении острой боли в спине. Эффективная фармакотерапия. Неврология и психиатрия. 2012;(5):36–40. Режим доступа: https://umedp.ru/articles/deksketoprofen_v_lechenii_ostroy_boli_v_spine.html.; Gaskell H., Derry S., Wiffen P.J., Moore R.A. Single dose oral ketoprofen or dexketoprofen for acute postoperative pain in adults. Cochrane Database Syst Rev. 2017;5(5):CD007355. https://doi.org/10.1002/14651858.CD007355.pub3.; Шавловская О.А. Оценка эффективности терапевтического действия препарата Дексалгин® (декскетопрофена трометамол) в лечении дорсопатии. Consilium Medicum. Неврология и ревматология (Прил.). 2012;(2):66–69. Режим доступа: https://omnidoctor.ru/library/izdaniyadlya-vrachey/consilium-medicum/cm2012/nevro_2012_pril/nevro2012_2_pril/otsenka-effektivnosti-terapevticheskogo-deystviya-preparata-deksalgin-deksketoprofena-trometamol-v-l/.; Moore R.A., Barden J. Systematic review of dexketoprofen in acute and chronic pain. BMC Clin Pharmacol. 2008;8:11. https://doi.org/10.1186/1472-6904-8-11

Availability: https://www.med-sovet.pro/jour/article/view/7641
https://doi.org/10.21518/ms2023-188

Cognitive functional therapy and non-steroidal anti-inflammatory drugs in the treatment of low back pain ; Когнитивно-функциональная терапия и нестероидные противовоспалительные средства в лечении боли в нижней части спины

Authors: O. E. Zinovyeva, A. A. Golovacheva, О. Е. Зиновьева, А. А. Головачева

Source: Meditsinskiy sovet = Medical Council; № 23 (2022); 78-85 ; Медицинский Совет; № 23 (2022); 78-85 ; 2658-5790 ; 2079-701X

Subject Terms: нимесулид, treatment, cognitive-behavioral therapy, nonsteroidal anti-inflammatory drugs, nimesulide, лечение, когнитивно-поведенческая терапия, нестероидные противовоспалительные средства

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7293/6515; Walker B.F. The prevalence of low back pain: a systematic review of the literature from 1966 to 1998. J Spinal Disord. 2000;13(3):205–217. https://doi.org/10.1097/00002517-200006000-00003.; Jordan K.P., Kadam U.T., Hayward R., Porcheret M., Young C., Croft P. Annual consultation prevalence of regional musculoskeletal problems in primary care: an observational study. BMC Musculoskelet Disord. 2010;11:144. https://doi.org/10.1186/1471-2474-11-144.; Парфенов В.А., Яхно Н.Н., Давыдов О.С., Кукушкин М.Л., Чурюканов М.В., Головачева В.А. и др. Хроническая неспецифическая (скелетно-мышечная) поясничная боль. Рекомендации Российского общества по изучению боли (РОИБ). Неврология, нейропсихиатрия, психосоматика. 2019;11(2S):7–16. https://doi.org/10.14412/2074-2711-2019-2S-7-16.; Парфенов В.А., Яхно Н.Н., Кукушкин М.Л., Чурюканов М.В., Давыдов О.С., Головачева В.А. и др. Острая неспецифическая (скелетно-мышечная) поясничная боль. Рекомендации Российского общества по изучению боли (РОИБ). Неврология, нейропсихиатрия, психосоматика. 2018;10(2):4–11. https://doi.org/10.14412/2074-2711-2018-2-4-11.; Airaksinen O., Brox J.I., Cedraschi C., Hildebrandt J., Klaber-Moffett J., Kovacs F. et al. Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J. 2006;15(Suppl. 2):S192–300. https://doi.org/10.1007/s00586-006-1072-1.; Kamper S.J., Apeldoorn A.T., Chiarotto A., Smeets R.J., Ostelo R.W., Guzman J., van Tulder M.W. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain: Cochrane systematic review and meta-analysis. BMJ. 2015;350:h444. https://doi.org/10.1136/bmj.h444.; Головачева В.А., Головачева А.А. Витамины группы В и нестероидные противовоспалительные препараты: эффективность комбинации при неспецифической боли в спине. Неврология, нейропсихиатрия, психосоматика. 2020;12(5):117–122. https://doi.org/10.14412/2074-2711-2020-5-117-122.; Головачева В.А., Головачева А.А., Зиновьева О.Е., Голубев В.Л. Толперизон в лечении острой и хронической неспецифической боли в спине. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):137–142. https://doi.org/10.14412/2074-2711-2020-4-137-142.; Кукушкин М.Л., Брылев Л.В., Ласков В.Б., Макаров Н.С., Пизова Н.В., Соков Е.Л. и др. Результаты рандомизированного двойного слепого параллельного исследования эффективности и безопасности применения толперизона у пациентов с острой неспецифической болью в нижней части спины. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(11):69–78. https://doi.org/10.17116/jnevro201711711169-78.; Calderon-Ospina C.A., Nava-Mesa M.O., Arbeláez Ariza C.E. Effect of Combined Diclofenac and B Vitamins (Thiamine, Pyridoxine, and Cyanocobalamin) for Low Back Pain Management: Systematic Review and Meta-analysis. Pain Med. 2020;21(4):766–781. https://doi.org/10.1093/pm/pnz216.; Mibielli M.A., Geller M., Cohen J.C., Goldberg S.G., Cohen M.T., Nunes C.P. et al. Diclofenac plus B vitamins versus diclofenac monotherapy in lumbago: the DOLOR study. Curr Med Res Opin. 2009;25(11):2589–2599. https://doi.org/10.3111/13696990903246911.; Vitoula K., Venneri A., Varrassi G., Paladini A., Sykioti P., Adewusi J., Zis P. Behavioral Therapy Approaches for the Management of Low Back Pain: An Up-To-Date Systematic Review. Pain Ther. 2018;7(1):1–12. https://doi.org/10.1007/s40122-018-0099-4.; Головачева В.А., Головачева А.А., Фатеева Т.Г. Психологические методы в лечении хронической неспецифической боли в нижней части спины. Неврология, нейропсихиатрия, психосоматика. 2019;11(2S):25–32. https://doi.org/10.14412/2074-2711-2019-2S-25-32.; Головачева А.А., Головачева В.А., Парфенов В.А. Кинезиотерапия и нестероидные противовоспалительные препараты при неспецифической люмбалгии. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):89–96. https://doi.org/10.14412/2074-2711-2022-1-89-96.; Oliveira C.B., Maher C.G., Pinto R.Z., Traeger A.C., Lin C.C., Chenot J.F. et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018;27(11):2791–2803. https://doi.org/10.1007/s00586-018-5673-2.; Vibe Fersum K., Smith A., Kvåle A., Skouen J.S., O’Sullivan P. Cognitive functional therapy in patients with non-specific chronic low back pain-a randomized controlled trial 3-year follow-up. Eur J Pain. 2019;23(8):1416–1424. https://doi.org/10.1002/ejp.1399.; Cutforth G., Peter A., Taenzer P. The Alberta Health Technology Assessment (HTA) Ambassador Program: The Development of a Contextually Relevant, Multidisciplinary Clinical Practice Guideline for Non-specific Low Back Pain: A Review. Physiother Can. 2011;63(3):278–286. https://doi.org/10.3138/ptc.2009-39P.; Головачева В.А., Головачева А.А., Фатеева Т.Г. Клинические принципы диагностики и лечения скелетно-мышечной (неспецифической) боли в нижней части спины. Неврология, нейропсихиатрия, психосоматика. 2021;13(3):107–112. https://doi.org/10.14412/2074-2711-2021-3-107-112.; Hong J.Y., Song K.S., Cho J.H., Lee J.H. An Updated Overview of Low Back Pain Management in Primary Care. Asian Spine J. 2017;11(4):653–660. https://doi.org/10.4184/asj.2017.11.4.653.; Letzel J., Angst F., Weigl M.B. Multidisciplinary biopsychosocial rehabilitation in chronic neck pain: a naturalistic prospective cohort study with intraindividual control of effects and 12-month follow-up. Eur J Phys Rehabil Med. 2019;55(5):665–675. https://doi.org/10.23736/S1973-9087.18.05348-0.; Парфенов В.А., Головачева В.А. Хроническая боль и ее лечение в неврологии. М.: ГЭОТАР-Медиа; 2018. 288 с.; Парфенов В.А., Исайкин А.И. Боль в нижней части спины: мифы и реальность. М.: ИМА-ПРЕСС; 2016. 104 с.; O’Keeffe M., O’Sullivan P., Purtill H., Bargary N., O’Sullivan K. Cognitive functional therapy compared with a group-based exercise and education intervention for chronic low back pain: a multicentre randomised controlled trial (RCT). Br J Sports Med. 2020;54(13):782–789. https://doi.org/10.1136/bjsports-2019-100780.; Conway D., Ladlow P., Ferreira J., Mani-Babu S., Bennett A.N. Cognitive functional therapy (CFT)-based rehabilitation improves clinical outcomes in UK military personnel with persistent low back pain. BMJ Mil Health. 2020;166(5):336–341. https://doi.org/10.1136/jramc-2018-001136.; Парфенов В.А. Ведение пациентов с хронической неспецифической поясничной болью. Медицинский совет. 2019;(1):40–45. https://doi.org/10.21518/2079-701X-2019-1-40-45.; Каратеев А.Е. Нестероидные противовоспалительные препаратыв современной клинической практике: «за» больше, чем «против». Современная ревматология. 2008;2(1):70–78. https://doi.org/10.14412/1996-7012-2008-463.; Насонов Е.Л., Яхно Н.Н., Каратеев А.Е., Алексеева Л.И., Баринов А.Н., Барулин А.Е. и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016;54(3):247–265. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2206.; Laporte J.R., Ibáñez L., Vidal X., Vendrell L., Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27(6):411–420. https://doi.org/10.2165/00002018-200427060-00005.; García Rodríguez L.A., Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007;132(2):498–506. https://doi.org/10.1053/j.gastro.2006.12.007.; Xu S., Rouzer C.A., Marnett L.J. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life. 2014;66(12):803–811. https://doi.org/10.1002/iub.1334.; Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т., Мартынов А.И., Яхно Н.Н., Арутюнов Г.П. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56:1–29. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2536/1691.; Bjarnason I. Therapeutic Roles of Selective COX-2 Inhibitors: Edited by J R Vane, R M Botting. William Harvey Press, 2001. ISBN-0 9534039-1-2. Gut. 2003;52(5):773. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773661/.; Bree F., Nguyen P., Urien S., Albengres E., Macciocchi A., Tillement J.P. Nimesulide binding to components within blood. Drugs. 1993;46(Suppl. 1): 83–90. https://doi.org/10.2165/00003495-199300461-00016.; Bunczak-Reeh M.A., Hargreaves K.M. Effect of inflammation on the delivery of drugs to dental pulp. J Endod. 1998;24(12):822–825. https://doi.org/10.1016/S0099-2399(98)80010-1.; Castellsague J., Riera-Guardia N., Calingaert B., Varas-Lorenzo C., Fourrier-Reglat A., Nicotra F. et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127–1146. https://doi.org/10.2165/11633470-000000000-00000.; Conforti A., Leone R., Moretti U., Mozzo F., Velo G. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf. 2001;24(14):1081–1090. https://doi.org/10.2165/00002018-200124140-00006.; Каратеев А.Е., Каратеев Д.Е., Насонов Е.Л. Гастродуоденальная переносимость нимесулида (нимесил, Berlin Chemie) у больных ревматическими заболеваниями с язвенным анамнезом. Научно-практическая ревматология. 2003;41(1):36–39. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/1050/723.; Traversa G., Bianchi C., Da Cas R., Abraha I., Menniti-Ippolito F., Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ. 2003;327(7405):18–22. https://doi.org/10.1136/bmj.327.7405.18.; Kress H.G., Baltov A., Basiński A., Berghea F., Castellsague J., Codreanu C. et al. Acute pain: a multifaceted challenge – the role of nimesulide. Curr Med Res Opin. 2016;32(1):23–36. https://doi.org/10.1185/03007995.2015.1100986.; Helin-Salmivaara A., Virtanen A., Vesalainen R., Grönroos J.M., Klaukka T., Idänpään-Heikkilä J.E., Huupponen R. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nation-wide case-control study from Finland. Eur Heart J. 2006;27(14):1657–1663. https://doi.org/10.1093/eurheartj/ehl053.; Барскова В.Г., Насонова В.А., Цапина Т.Н., Каратеев А.Е., Якунина И.А., Елисеев М.С. и др. Эффективность и безопасность применения Нимесила при подагрическом артрите. Клиническая медицина. 2004;82(12):49–54. Режим доступа: https://www.elibrary.ru/item.asp?id=17088793.; Aw T.J., Haas S.J., Liew D., Krum H. Meta-analysis of cyclooxygen-ase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165(5):490–496. https://doi.org/10.1001/archinte.165.5.IOI50013.; Егоров И.В., Цурко В.В. Особенности лечения суставного синдрома у лиц пожилого возраста с артериальной гипертензией. Современная ревматология. 2008;2(4):52-54. https://doi.org/10.14412/1996-7012-2008-508.; Алексеева Л.И., Каратеев А.Е., Попкова Т.В., Новикова Д.С., Шарапова Е.П., Маркелова Е.П., Насонов Е.Л. Эффективность и безопасность длительного применения нимесулида у больных остеоартрозом: результаты 12-месячного открытого контролируемого исследования ДИНАМО (Длительное Использование Нимесулида при Артрозе Многофакторная Оценка). Научно-практическая ревматология. 2009;47(4):64–72. https://doi.org/10.14412/1995-4484-2009-1152.; Pohjolainen T., Jekunen A., Autio L., Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine (Phila Pa 1976). 2000;25(12):1579–1585. https://doi.org/10.1097/00007632-200006150-00019.; Каратеев А.Е., Лила А.М., Чурюканов М.В., Скоробогатых К.В., Амелин А.В., Захаров Д.В. и др. Оценка эффективности алгоритма назначения нестероидных противовоспалительных препаратов (НПВП), основанного на анализе факторов риска лекарственных осложнений, в реальной клинической практике. Результаты всероссийского проекта «ПРИНЦИП» (Применение Рекомендаций по Использованию НПВП: Целенаправленное Изменение Практики). Научно-практическая ревматология. 2017;55(5):485–492. https://doi.org/10.14412/1995-4484-2017-485-492.; Шихкеримов Р.К. Применение нимесулида в терапии острой боли в нижней части спины. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(5):28–32. https://doi.org/10.17116/jnevro20161165128-32.; Binning A. Nimesulide in the treatment of postoperative pain: a double-blind, comparative study in patients undergoing arthroscopic knee surgery. Clin J Pain. 2007;23(7):565–570. https://doi.org/10.1097/AJP.0b013e3180e00dff.

Availability: https://www.med-sovet.pro/jour/article/view/7293
https://doi.org/10.21518/2079-701X-2022-16-23-78-85

Thoughts about choice of anti-inflammatory therapy in endodontics

Source: Эндодонтия Today, Vol 14, Iss 1, Pp 42-46 (2020)

Subject Terms: эндодонтия, фармакотерапия, противовоспалительные средства, глюкокортикоиды, нестероидные противовоспалительные средства (нпвс), фармакокинетика нпвс, endodontics, pharmacotherapy, anti-inflammatory drugs, glucocorticoids, non-steroidal anti-inflammatory drugs (nsaids), pharmacokinetics of nsaids, Dentistry, RK1-715

File Description: electronic resource

Relation: https://www.endodont.ru/jour/article/view/323; https://doaj.org/toc/1683-2981; https://doaj.org/toc/1726-7242

Access URL: https://doaj.org/article/927e991d295d4fada4e18633183ebcb5

Drug-Induced Atrial Fibrillation / Atrial Flutter ; Лекарственно-индуцированная фибрилляция/трепетание предсердий

Authors: O. Ostroumova D, M. Chernyaeva S., A. Kochetkov I., A. Vorobieva E., D. Bakhteeva I., S. Korchagina P., O. Bondarets V., N. Boyko D., D. Sychev A., О. Остроумова Д., М. Черняева С., А. Кочетков И., А. Воробьева Е., Д. Бахтеева И., С. Корчагина П., О. Бондарец В., Н. Бойко Д., Д. Сычев А.

Source: Rational Pharmacotherapy in Cardiology; Vol 17, No 6 (2021); e1-e18 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 6 (2021); e1-e18 ; 2225-3653 ; 1819-6446

Subject Terms: drug-induced atrial fibrillation, adverse drug reactions, anticancer drugs, bisphosphonates, glucocorticoids, nonsteroidal anti-inflammatory drugs, immunosuppressants, local anesthetics, anabolic steroids, nicotine, лекарственно-индуцированная фибрилляция предсердий, нежелательные лекарственные реакции, противоопухолевые лекарственные средства, бисфосфонаты, глюкокортикоиды, нестероидные противовоспалительные средства, иммунодепрессанты, местные анестетики, анаболические стероиды, никотин

File Description: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2636/2269; 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.; 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609-78. DOI:10.1093/europace/euw295.; Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-52. DOI:10.1161/01.cir.98.10.946.; Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. The Am J Med. 2002;113(5):359-64. DOI:10.1016/s0002-9343(02)01236-6.; Andersson T, Magnuson A, Bryngelsson IL, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case control study. Eur Heart J. 2013;34(14):1061-7. DOI:10.1093/eurheartj/ehs469.; Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44(11):3103-8. DOI:10.1161/STROKEAHA.113.00232.; Haim M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4(1):e001486. DOI:10.1161/JAHA.114.001486.; Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47. DOI:10.1161/CIRCULATIONAHA.113.00511.; Wolf PA, Abbott R, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22(8):983-8. DOI:10.1161/01.str.22.8.983.; Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000;36(7):2242-6. DOI:10.1016/s0735-1097(00)00982-7.; Halligan SC, Gersh BJ, Brown RD Jr, et al. The natural history of lone atrial flutter. Ann Intern Medю 2004;140(4):265-8. DOI:10.7326/0003-4819-140-4-200402170-00008.; Фибрилляция и трепетание предсердий. Клинические рекомендации 2020 г.» [цитировано 30.06.2021. Доступно на: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf].; Dobrev D, Friedrich A, Voigt N, et al. The G protein-gated potassium current I (K, A Ch) is constitutively active in patients with chronic atrial fibrillation. Circulation. 2005;112(24):3697-706. DOI:10.1161/CIRCULATIONAHA.105.575332.; Van Wagoner DR, Pond AL, Lamorgese M, et al. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res. 1999;85(5):428-36. DOI:10.1161/01.res.85.5.428.; van der Hooft CS, Heeringa J, van HG, et al. Drug-induced atrial fibrillation. J Am Coll Cardiol. 2004;44(11):2117-24. DOI:10.1016/j.jacc.2004.08.053; Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018; Остроумова О.Д., Черняева М.С., Комарова А.Г., и др. Лекарственно-индуцированная фибрилляция предсердий, ассоциированная с приемом сердечно-сосудистых лекарственных средств. Сибирское Медицинское Обозрение. 2020;(6):5-13. DOI:10.20333/2500136-2020-6-5-13.; Tamargo J, Caballero R, Delpón E. Drug-induced atrial fibrillation: does it matter? Discovery Medicine. 2012;14(78):295-9.; Остроумова О.Д., Черняева М.С., Масленникова О.М., и др. Лекарственно-индуцированная фибрилляция/трепетание предсердий, ассоциированная с приемом лекарственных средств, влияющих на центральную нервную систему. Фарматека. 2021;(3):10-7. DOI:10.18565/pharmateca.; Остроумова О.Д., Черняева М.С., Кочетков А.И., и др. Лекарственно-индуцированная фибрилляция предсердий, ассоциированная с применением противоопухолевых лекарственных средств. Безопасность и Риск Фармакотерапии. 2020;8(4):178-90. DOI:10.30895/2312-7821-2020-8-4-178-190.; Остроумова О.Д., Черняева М.С., Бахтеева Д.И., и др. Отдельные группы лекарственных средств, прием которых ассоциирован с развитием лекарственно-индуцированной фибрилляции предсердий. Медицинский Алфавит. 2021;1(11):20-8. DOI:10.33667/2078-5631-2021-11-20-28.; Strickberger SA, Man KC, Daoud EG. Adenosine-induced Atrial Arrhythmia: A Prospective Analysis. Ann Intern Med. 1997;127(6):417-22. DOI:10.7326/0003-4819-127-6-199709150-00001; Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation. 1999;99(8):1034-40. DOI:10.1161/01.cir.99.8.1034.; Camaiti A, Pieralli F, Olivotto I, et al. Prospective evaluation of adenosine-induced proarrhythmia in the emergency room. Eur J Emerg Med. 2001;8(2):99-105 DOI:10.1097/00063110-200106000-00005.; Belhassen B, Pelleg A, Shoshani D. Atrial Fibrillation Induced by Adenosine Triphosphate. Am J Cardiol. 1984;53(9):1405-6. DOI:10.1016/0002-9149(84)90104-8.; Garratt CJ, Antoniou A, Griffith MJ, Ward DE. Use of Intravenous Adenosine in Sinus Rhythm as a Diagnostic Test for Latent Preexcitation. Am J Cardiol. 1990;65(13):868-73. DOI:10.1016/0002-9149(90)91428-9.; Meurer MK. A 21-year-old Woman With Rapid Atrial Fibrillation After Adenosine Administration. J Emerg Nurs. 1991;17(3):135-6.; Cowell RP, Paul VE, Ilsley CD. Haemodynamic Deterioration After Treatment With Adenosine. Br Heart J. 1994;71(6):569-71. DOI:10.1136/hrt.71.6.569.; Crosson JE, Etheridge SP, Milstein S. Therapeutic and Diagnostic Utility of Adenosine During Tachycardia Evaluation in Children. Am J Cardiol. 1994;74(2):155-60. DOI:10.1016/0002-9149(94)90089-2.; Tebbenjohanns J, Pfeiffer D, Schumacher B, et al. Intravenous Adenosine During Atrioventricular Reentrant Tachycardia: Induction of Atrial Fibrillation With Rapid Conduction Over an Accessory Pathway. Pacing Clin Electrophysiol. 1995;18(4):743-6. DOI:10.1111/j.1540-8159.1995.tb04673.x.; Silverman AJ, Machado C, Baga JJ, et al. Adenosine-induced Atrial Fibrillation. Am J Emerg Med. 1996;14(3):300-1. DOI:10.1016/S0735-6757(96)90182-5.; Kaplan IV, Kaplan AV, Fisher JD. Adenosine Induced Atrial Fibrillation Precipitating Polymorphic Ventricular Tachycardia. Pacing Clin Electrophysiol. 2000;23(1):140-1. DOI:10.1111/j.1540-8159.2000.tb00662.x; Israel C, Klingenheben T, Grönefeld G. Adenosine-induced Atrial Fibrillation. J Cardiovasc Electrophysiol. 2000;11(7):825. DOI:10.1111/j.1540-8167.2000.tb00057.x.; Jonathan RK, Ronn ET, Maully JSh, et al. Induction of Atrial Fibrillation After the Routine Use of Adenosine. Pediatr Emerg Care. 2006;22(2):113-5. DOI:10.1097/01.pec.0000199558.88733.49.; Matthew C, Jaffar R, Assad M. Atrial Fibrillation During Adenosine Pharmacologic Stress Testing. J Nucl Cardiol. 2006;13(4):576-81. DOI:10.1016/j.nuclcard.2006.05.006.; Stuber T, Lim PB, O'Neill MD, Peters NS. Ultra Rapid Local Activity in Adenosine-Induced Atrial Fibrillation. J Cardiovasc Electrophysiol. 2008;19(5):566-7. DOI:10.1111/j.1540-8167.2007.01044.x.; Kanei Y, Hanon S, Van-Tosh A, Schweitzer P. Adenosine-induced Atrial Fibrillation During Pharmacologic Stress Testing: Report of Eight Cases and Review of the Literature. Int J Cardiol. 2008;129(1):e15-7. DOI:10.1016/j.ijcard.2007.05.090.; Turley AJ, Murray S, Thambyrajah J. Pre-excited Atrial Fibrillation Triggered by Intravenous Adenosine: A Commonly Used Drug With Potentially Life-Threatening Adverse Effects. Emerg Med J. 2008;25(1):46-8. DOI:10.1136/emj.2007.051227.; Park E, Price A, Vidovich MI. Adenosine-induced Atrial Fibrillation During Fractional Flow Reserve Measurement. Cardiol J. 2012;19(6):650-1. DOI:10.5603/cj.2012.0121.; Walter JHJr, Patricia ETh, Christopher SS. Induction of Atrial Fibrillation With Adenosine During a Transesophageal Electrophysiology Study to Risk Stratify a Patient With Asymptomatic Ventricular Preexcitation. Congenit Heart Dis. 2013;8(4):E99-E101. DOI:10.1111/j.1747-0803.2012.00682.x.; Salaria V, Mehta NJ, Abdul-Aziz S, et al. Role of postoperative use of adrenergic drugs in occurrence of atrial fibrillation after cardiac surgery. Clin Cardiol. 2005;28(3):131-5. DOI:10.1002/clc.4960280306.; Kane GC, Hepinstall MJ, Kidd GM, et al. Safety of stress echocardiography supervised by registered nurses: results of a 2-year audit of 15,404 patients. J Am Soc Echocardiogr. 2008;21(4):337-41. DOI:10.1016/j.echo.2007.08.028.; Carasso S, Sandach A, Kuperstein R, et al. Atrial fibrillation in dobutamine stress echocardiography. Int J Cardiol. 2006;111(1):53-8. DOI:10.1016/j.ijcard.2005.07.001.; Mertes H, Sawada SG, Ryan T, et al. Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Experience in 1118 patients. Circulation. 1993;88:15-9. DOI:10.1161/01.cir.88.1.15.; Secknus MA, Marwick TH. Evolution of dobutamine echocardiography protocols and indications: safety and side effects in 3,011 studies over 5 years. J Am Coll Cardiol. 1997;29(6):1234-40. DOI:10.1016/s0735-1097(97)00039-9.; Feneck RO, Sherry KM, Withington PS, et al. Comparison of the Hemodynamic Effects of Milrinone With Dobutamine in Patients After Cardiac Surgery. J Cardiothorac Vasc Anesth. 2001;15(3):30615. DOI:10.1053/jcan.2001.23274.; Baig MW, Sheard K, Thorley PJ, et al. The Use of Dobutamine Stress Thallium Scintigraphy in the Diagnosis of Syndrome X. Postgrad Med J. 1992;68 Suppl 2:S20-4.; Poldermans D, Fioretti PM, Boersma E. et al. Safety of Dobutamine-Atropine Stress Echocardiography in Patients With Suspected or Proven Coronary Artery Disease. Am J Cardiol. 1994;73(7):456-9. DOI:10.1016/0002-9149(94)90675-0.; Wirtz CE. Sustained Atrial Fibrillation After Dobutamine Stress Echocardiography in an Older Patient With Left Atrial Enlargement. West J Med. 1995;162(3):268-9.; Cornel JH, Balk AH, Boersma E, et al. Safety and feasibility of dobutamine-atropine stress echocardiography in patients with ischemic left ventricular dysfunction. J Am Soc Echocardiogr. 1996;9(1):27-32. DOI:10.1016/s0894-7317(96)90101-7.; Yeo TC, Ng WL, Ling LH, et al. Dobutamine stress echocardiography in the elderly Asian patients. Ann Acad Med Singap. 1997;26(2):165-7.; Pezzano A, Gentile F, Mantero A, et al. [RITED (RegistroItaliano Test Eco-Dobutamina): side effects and complications of echo-dobutamine stress test in 3041 examinations]. Giornaleitaliano di Cardiologia. 1998;28(2):102-11 (In Italian).; Elhendy A, van Domburg RT, Bax JJ, et al. Safety, hemodynamic profile, and feasibility of dobutamine stress technetium myocardial perfusion single-photon emission CT imaging for evaluation of coronary artery disease in the elderly. Chest. 2000;117(3):649-56. DOI:10.1378/chest.117.3.649.; Coisne D, Donal E, Torremocha F, et al. Dobutamine stress echocardiography response of asymptomatic patients with diabetes. Echocardiography. 2001;18(5):373-9. DOI:10.1046/j.1540-8175.2001.00373.x.; Cortigiani L, Zanetti L, Bigi R, et al. Safety and feasibility of dobutamine and dipyridamole stress echocardiography in hypertensive patients. J Hypertens. 2002;20(7):1423-9. DOI:10.1097/00004872-200207000-00030.; Wahl A, Paetsch I, Gollesch A, et al. Safety and feasibility of high-dose dobutamine-atropine stress cardiovascular magnetic resonance for diagnosis of myocardial ischaemia: experience in 1000 consecutive cases. Eur Heart J. 2004;25(14):1230-6. DOI:10.1016/j.ehj.2003.11.018.; Onorati F, Renzulli A, De Feo M, et al. Perioperative enoximone infusion improves cardiac enzyme release after CABG. J Cardiothorac Vasc Anesth. 2004;18(4):409-14 DOI:10.1053/j.jvca.2004.05.016.; Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297(17):1883-91. DOI:10.1001/jama.297.17.1883.; Sheldon SH, Askew JW 3rd, Klarich KW, et al. Occurrence of atrial fibrillation during dobutamine stress echocardiography: incidence, risk factors, and outcomes. J Am Soc Echocardiogr. 2011;24(1):86-90. DOI:10.1016/j.echo.2010.10.008.; Argalious M, Motta P, Khandwala F, et al. "Renal dose" dopamine is associated with the risk of newonset atrial fibrillation after cardiac surgery. Crit Care Med. 2005;33(6):1327-32. DOI:10.1097/01.ccm.0000166876.41694.ca.; Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287(12):1541–7. DOI:10.1001/jama.287.12.1541.; Wright EM, Sherry KM. Clinical and haemodynamic effects of milrinone in the treatment of low cardiac output after cardiac surgery. Br J Anaesth. 1991;67(5):585-90. DOI:10.1093/bja/67.5.585.; Feneck RO. Intravenous milrinone following cardiac surgery: II. Influence of baseline hemodynamics and patient factors on therapeutic response. The European Milrinone Multicentre Trial Group. J Cardiothorac Vasc Anesth. 1992;6(5):563-7. DOI:10.1016/1053-0770(92)90098-r.; Fleming GA, Murray KT, Yu C, et al. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. Circulation. 2008;118(16):1619-25. DOI:10.1161/CIRCULATIONAHA.108.790162.; Smith AH, Owen J, Borgman KY, et al. Relation of milrinone after surgery for congenital heart disease to significant postoperative tachyarrhythmias. Am J Cardiol. 2011;108(11):1620-4. DOI:10.1016/j.amjcard.2011.07.023.; Acharya D, Sanam K, Revilla-Martinez M, et al. Infections, Arrhythmias, and Hospitalizations on Home Intravenous Inotropic Therapy. Am J Cardiol. 2016;117(6):952-6. DOI:10.1016/j.amj-card.2015.12.030.; Tai CT, Chiang CE, Lee SH, et al. Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. J Cardiovasc Electrophysiol. 1999;10(9):1180-7. DOI:10.1111/j.1540-8167.1999.tb00293.x.; Donald HSc, Melissa SD. Paroxysmal Atrial Fibrillation Precipitated by Amiodarone-Induced Thyrotoxicosis Five Months After Cessation of Therapy. J Emerg Med. 2006;31(1):61-4. DOI:10.1016/j.jemermed.2005.08.011.; Ibrahim HK, Talat Y, Bulent MK. Atrial Fibrillation Due to Late Amiodarone-Induced Thyrotoxicosis. Clin Drug Investig. 2008;28(8):527-31. DOI:10.2165/00044011-200828080-00008.; Остроумова О.Д., Качан В.О., Кочетков А.И., Краснов Г.С. Лекарственно-индуцированный гипотиреоз. Фарматека. 2020;27(3):107-17. DOI:10.18565/pharmateca.2020.3.107-117.; Гайсёнок О.В. Нарушения сердечного ритма в реальной врачебной практике: амиодарон-индуцированный тиреотоксикоз 2-го типа как причина рецидивирующей фибрилляции предсердий. Рациональная Фармакотерапия в Кардиологии. 2010;6(4):518-21. DOI:10.20996/1819-6446-2010-6-4-518-521.; Reithmann C, Hoffmann E, Spitzlberger G, et al. Catheter Ablation of Atrial Flutter Due to Amiodarone Therapy for Paroxysmal Atrial Fibrillation. Eur Heart J. 2000;21(7):565-72. DOI:10.1053/euhj.1999.1865.; Kaakeh Y, Overholser BR, Lopshire JC, Tisdale E. Drug-Induced Atrial Fibrillation. Drugs. 2012;72(12):1617-30. DOI:10.2165/11633140-000000000-00000.; Tamargo J, Delpon E, Caballero R. The safety of digoxin as a pharmacological treatment of atrial fibrillation. Expert Opin Drug Saf. 2006;5(3):453-67. DOI:10.1517/14740338.5.3.453.; Sticherling C, Oral H, Horrocks J, et al. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation. 2000;102(20):2503-8. DOI:10.1161/01.cir.102.20.2503.; Digitalis Investigation Group. The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. New Engl J Med. 1997;336(8):525-33. DOI:10.1056/NEJM199702203360801.; Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871-8. DOI:10.1001/jama.289.7.871.; Мареев В.Ю., Фомин И.В., Агеев Ф.Т, и др. Клинические рекомендации ОССН-РКО-РНМОТ. сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158. DOI:10.18087/cardio.2475.; Nabar A, Rodriguez LM, Timmermans C, et al. Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation. Heart. 2001;85(4):424-9. DOI:10.1136/heart.85.4.424.; Murdock CJ. Atrial Flutter in Patients Treated for Atrial Fibrillation With Propafenone. Am J Cardiol. 1990;66(7):755-7. DOI:10.1016/0002-9149(90)91144-u.; Feld GK, Chen PS, Nicod P, et al. Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs. Am J Cardiol. 1990;66(3):378-83. DOI:10.1016/0002-9149(90)90856-v.; Aliot E, De Roy L, Capucci A, et al. Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients. Ann Cardiol Angéiol (Paris). 2003;52(1):34-40. DOI:10.1016/s0003-3928(02)00183-x.; Shenasa M, Kus T, Fromer M, et al. Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation. Am J Cardiol. 1988;62(7):403-7. DOI:10.1016/0002-9149(88)90967-8.; Isomoto S, Shimizu A, Knoe A, et al. Effects of intravenous verapamil on atrial vulnerability. Jpn Circ J. 1994;58(1):1-8. DOI:10.1253/jcj.58.1.; Falk RH. Etiology and complications of atrial fibrillation: insights from pathology studies. Am J Cardiol. 1998;82(8A):10N-17N. DOI:10.1016/s0002-9149(98)00735-8.; Falk RH, Knowlton AA, Manaker S. Verapamil-induced Atrial Fibrillation. N Engl J Med. 1988;318(10):640-1. DOI:10.1056/NEJM198803103181014.; Garratt C, Linker N, Griffith M, et al. Comparison of Adenosine and Verapamil for Termination of Paroxysmal Junctional Tachycardia. Am J Cardiol. 1989;64(19):1310-6. DOI:10.1016/0002-9149(89)90573-0.; Parasuraman R, Gandhi MM, Liversedge NH. Nifedipine tocolysis associated atrial fibrillation responds to DC cardioversion. BJOG. 2006;113(7):844-5. DOI:10.1111/j.1471-0528.2006.00964.x.; Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-85. DOI:10.1016/S0140-6736(10)61198-1.; Fox K, Ford I, Gabriel Ph, et al. Jean-Claude Tardif, Michal Tendera, Roberto Ferrari, SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091-9. DOI:10.1056/NEJMoa1406430.; Fox K, Ford I, Gabriel Ph, et al. Bradycardia and Atrial Fibrillation in Patients With Stable Coronary Artery Disease Treated With Ivabradine: An Analysis From the SIGNIFY Study. Eur Heart J. 2015;36(46):3291-6. DOI:10.1093/eurheartj/ehv451.; Cammarano C, Silva M, Comee M, et al. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction. Clini Ther. 2016;38(2):387-95. DOI:10.1016/j.clinthera.2015.12.018.; Mengesha HG, Weldearegawi B, Petrucka P, et al. Effect of Ivabradine on Cardiovascular Outcomes in Patients With Stable Angina: Meta-Analysis of Randomized Clinical Trials. BMC Cardiovasc Disord. 2017;17(1):105. DOI:10.1186/s12872-017-0540-3.; Martin RI, Pogoryelova O. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014;100(19):1506-10. DOI:10.1136/heartjnl-2014-305482.; Tanboğa İH, Topçu S, Aksakal E, et al. The Risk of Atrial Fibrillation With Ivabradine Treatment: A Metaanalysis With Trial Sequential Analysis of More Than 40000 Patients. Clin Cardiol. 2016;39(10):615-20. DOI:10.1002/clc.22578.; Emara MK, Saadet AM. Transient atrial fibrillation in hypertensive patients with thiazide induced hypokalaemia. Postgrad Med J. 1986;62(734):1125-7. DOI:10.1136/pgmj.62.734.1125.; Zhang N, Chen K, Zhao J, et al. Another Side Effect of Ticagrelor: Atrial Fibrillation. Int J Cardiol. 2016;212:242-4. DOI:10.1016/j.ijcard.2016.03.091.; McCune KH, O’Brien CJ. Atrial fibrillation induced by ibuprofen overdose. Postgrad Med J. 1993;69(810):325-6. DOI:10.1136/pgmj.69.810.325-a.; Vasheghani-Farahani A, Sahraian MA, Darabi L, et al. Incidence of Various Cardiac Arrhythmias and Conduction Disturbances Due to High Dose Intravenous Methylprednisolone in Patients With Multiple Sclerosis. J Neurol Sci. 2011;309(1-2):75-8. DOI:10.1016/j.jns.2011.07.018.; McLuckie AE, Savage RW. Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest. 1993;104(2):622-3. DOI:10.1378/chest.104.2.622.; Moretti R, Torre P, Antonello RM, et al Recurrent atrial fibrillation associated with pulse administration of high doses of methylprednysolone: a possible prophylactic treatment. Eur J Neurol. 2000;7(1):130. DOI:10.1046/j.1468-1331.2000.00026.x.; Ueda N, Yoshikawa T, Chihara M, et al. Atrial fibrillation following methylprednisolone pulse therapy. Pediatr Nephrol. 1988;2(1):29-31. DOI:10.1007/BF00870376.; Yamamura K, Ohga S, Nishiyama K, et al. Recurrent atrial fibrillation after high-dose methylprednisolone therapy in a girl with lupus-associated hemophagocytic syndrome. Lupus 2011;20(8):871-5. DOI:10.1177/0961203310392429.; Aslam AK, Vasavada BC, Sacchi TJ, Khan IA. Atrial fibrillation associated with systemic lupus erythematosus and use of methylprednisolone. Am J Ther. 2001;8(4):303–5. DOI:10.1097/00045391-200107000-00013.; Dogukan A, Ilkay E, Poyrazoglu OK, et al. Atrial fibrillation due to oral methylprednisolone in a patient with membranoproliferative glomerulonephritis. Acta Medica (Hradec Kralove). 2008;51(1):63-4. DOI:10.14712/18059694.2017.34.; Iqbal FM, Beeharilal PS, Sadat K, et al. Steroid induced atrial fibrillation. Compr Ther. 2008;34(2):111–4.; van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016-20. DOI:10.1001/archinte.166.9.1016.; De CR, Ruigomez A, Rodriguez LA. Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med. 2010;170(16):1450-5. DOI:10.1001/archinternmed.2010.305.; Oteri A, Bussolini A, Sacchi M, et al. A case of atrial fibrillation induced by inhaled fluticasone propionate. Pediatrics. 2010;126(5):e1237-41. DOI:10.1542/peds.2010-0419.; De Caterina R, Ruigomez A, Rodriguez LA. Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med. 2010;170(16):1450-5. DOI:10.1001/archinternmed.2010.305.; Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011;343:d3450. DOI:10.1136/bmj.d3450.; Merli GJ, Weitz H, Martin JH, et al. Cardiac dysrhythmias associated with ophthalmic atropine. Arch Intern Med. 1986;146(1):45-7.; Sueda S, Ochi N, Kawada H, et al. Frequency of provoked coronary vasospasm in patients undergoing coronary arteriography with spasm provocation test of acetylcholine. Am J Cardiol. 1999;83(8):1186-90. DOI:10.1016/s0002-9149(99)00057-0.; Sueda S, Fukuda H, Watanabe K, et al. Clinical characteristics and possible mechanism of paroxysmal atrial fibrillation induced by intracoronary injection of acetylcholine. Am J Cardiol. 2001;88(5):570-3. DOI:10.1016/s0002-9149(01)01744-1.; Low RA Jr, Fuller MA, Popli A. Clozapine induced atrial fibrillation. J Clin Psychopharmacol. 1998;18(2):170. DOI:10.1097/00004714-199804000-00010.; Shaibani A, Fares S, Selam, et al. Lacosamide in painful diabetic neuropathy: an 18-week double blind placebo controlled trial. J Pain. 2009;10(8):818-28. DOI:10.1016/j.jpain.2009.01.322.; De Giorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav. 2010;18(3):322-4. DOI:10.1016/j.yebeh.2010.04.043.; Lee CW, Muo CH, Liang JA, et al. Atrial Fibrillation is Associated With Morphine Treatment in Female Breast Cancer Patients: A Retrospective Population-Based Time-Dependent Cohort Study. Medicine (Baltimore). 2016;95(11):e3102. DOI:10.1097/MD.0000000000003102.; Peacock WF, Hollander JE, Diercks DB, et al. Morphine and Outcomes in Acute Decompensated Heart Failure: An ADHERE Analysis. Emerg Med J. 2008;25(4):205-9. DOI:10.1136/emj.2007.050419.; Sabzi F, Zokaei AH, Moloudi AR. Predictors of atrial fibrillation following coronary artery bypass grafting. Clin Med Insights Cardiol. 2011;5:67-75. DOI:10.4137/CMC.S7170.; Waters BM, Joshi KG, Flynn J. Olanzapine-Associated New-Onset Atrial Fibrillation. J Clin Psychopharmacol. 2008;28(3):354-5. DOI:10.1097/JCP.0b013e318173082c.; Davis LE, Becher MW, Tlomak W, et al. Persistent choreoathetosis in a fatal olanzapine overdose: drug kinetics, neuroimaging, and neuropathology. Am J Psychiatry. 2005;162(1):28-33. DOI:10.1176/appi.ajp.162.1.28.; Yaylaci S, Tamer A, Kocayigit I, Gunduz H. Atrıal fıbrıllatıon due to olanzapine overdose. Clin Toxicol (Phila). 2011;49(5):440. DOI:10.3109/15563650.2011.588605.; Kasinath NS, Malak O, Tetzlaff J. Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report. Can J Anaesth. 2003;50(3):229-31. DOI:10.1007/BF03017789.; Havrilla PL, Kane-Gill SL, Verrico MM, et al. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Ann Pharmacother. 2009;43(3):532-6. DOI:10.1345/aph.1L544.; Schneider RA, Lizer MH. Apparent seizure and atrial fibrillation associated with paliperidone. Am J Health Syst Pharm. 2008;65(22):2122-5. DOI:10.2146/ajhp070615.; Morgan DR, Trimble M, McVeigh GE. Atrial fibrillation associated with sumatriptan. BMJ. 2000;321(7256):275. DOI:10.1136/bmj.321.7256.275.; Devadathan S, Gunning M. Atrial fibrillation following oral sumatriptan administration. Int J Cardiol. 2006;107(1):112-3. DOI:10.1016/j.ijcard.2004.11.039.; White WB, Wong SH. Rapid atrial fibrillation associated with trazodone hydrochloride. Arch Gen Psychiatry. 1985;42(4):424. DOI:10.1001/archpsyc.1985.01790270114017.; Qureshi WT, O’Neal WT, Khodneva Y, et al. Association between opioid use and atrial fibrillation: the reasons for geographic and racial differences in stroke (REGARDS) study. JAMA Intern Med. 2015;175(6):1058-60. DOI:10.1001/jamainternmed.2015.1045.; Buff DD, Brenner R, Kirtane SS, Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry. 1991;52(4):174-6.; Roberge RJ, Martin G. Mixed fluoxetine/loxapine overdose and atrial flutter. Ann Emerg Med. 1994;23(3):586-90. DOI:10.1016/s0196-0644(94)70083-4.; Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20(1):205-13. DOI:10.1200/JCO.2002.20.1.205.; Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood. 2004;104(3):655-8. DOI:10.1182/blood-2003-07-2345.; Gridelli C, Cigolari S, Gallo C, et al. MILES Investigators. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 2001;31(2-3):277-84. DOI:10.1016/s0169-5002(00)00194-x.; Tavil Y, Arslan U, Okyay K, et al. Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man. Onkologie. 2007;30(5):253-5. DOI:10.1159/000100930.; Santini D, Tonini G, Abbate A, et al. Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. Ann Oncol. 2000;11(4):479-81. DOI:10.1023/a:1008380208045.; Ciotti R, Belotti G, Facchi E, et al. Sudden cardiopulmonary toxicity following a single infusion of gemcitabine. Ann Oncol. 1999;10(8):997. DOI:10.1023/a:1008305716918.; Ferrari D, Carbone C, Codeca C, et al. Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity. Anticancer Drugs. 2006;17(3):359-61. DOI:10.1097/00001813-200603000-00016.; Numico G, Castiglione F, Granetto C, et al. Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer. 2002;35(1):59-64. DOI:10.1016/s0169-5002(01)00269-0.; Kilickap S, Barista I, Akgul E, et al. Early and late arrhythmogenic effects of doxorubicin. South Med J. 2007;100(3):262-5. DOI:10.1097/01.smj.0000257382.89910.fe.; Dindogru A, Barcos M, Henderson ES, Wallace HJJr. Electrocardiographic changes following adriamycin treatment. Med Pediatr Oncol. 1978;5(1):65-71. DOI:10.1002/mpo.2950050110; Oster MW, Rakowski TJ. Myocardial injury immediately following adriamycin administration. Med Pediatr Oncol. 1981;9(5):463-5. DOI:10.1002/mpo.2950090508.; Montella L, Caraglia M, Addeo R, et al. Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert’s disease). Ann Hematol. 2005;84(3):192-3. DOI:10.1007/s00277-004-0867-6.; Palma M, Mancuso A, Grifalchi F. Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report. Tumori 2002;88(6):527-9.; Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138-40. DOI:10.1182/blood-2016-05-712828.; Yun S, Vincelette ND, Acharya U, Abraham I. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk. 2017;17(1):31-37.e13. DOI:10.1016/j.clml.2016. 09.010.; Caldeira D, Alves D, Costa J, et al. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One 2019;14(2):e0211228. DOI:10.1371/journal.pone.0211228.; Емелина Е.И., Гендлин Г.Е., Никитин И.Г., и др. Нарушения ритма и проводимости у пациентов, получающих лечение ибрутинибом. Клиническая Онкогематология. 2019;12(2):220-30. DOI:10.21320/2500-2139-2019-12-2-220-230.; Shanafelt TD, Parikh SA, Noseworthy PA, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017;58(7):1630–9. DOI:10.1080/10428194.2016.1257795.; Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1989;7(1):7-20. DOI:10.1200/JCO.1989.7.1.7.; Dutcher JP, Fisher RI, Weiss G, et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am. 1997;3(3):157-62.; Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989;7(4):486-98. DOI:10.1200/JCO.1989.7.4.486.; Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118(1):31-6. DOI:10.7326/0003-4819-118-1-199301010-00006.; Illiano A, Barletta E, De Marino V, et al. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study. Anticancer Res. 2000;20(5C):3999–4003.; Pérez PE, Mesa MG, García SPJ, González RAP. Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. Adv Ther. 2011;28 Suppl 1:11-6. DOI:10.1007/s12325-010-0102-x.; Olivieri A, Corvatta L, Montanari M, et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant. 1998;21(10):1049-53. DOI:10.1038/sj.bmt.1701217.; Moreau P, Milpied N, Mahé B, et al. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant. 1999;23(10):1003-6. DOI:10.1038/sj.bmt.1701763.; Phillips GL, Meisenberg B, Reece DE, et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant. 2004;10(7):473-83. DOI:10.1016/j.bbmt.2004.03.001.; Feliz V, Saiyad S, Ramarao SM, et al. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol. 2011;34(6):356-9. DOI:10.1002/clc.20904.; Sirohi B, Powles R, Treleaven J, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 2000;25(5):533-9. DOI:10.1038/sj.bmt.1702188.; Mileshkin LR, Seymour JF, Wolf MM, et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stern cell transplantation for patients aged 60 years and older. Leuk Lymphoma. 2005;46(11):1575-9. DOI:10.1080/1042819050023588.; Zingler VC, Nabauer M, Jahn K. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Eur Neurol. 2005;54(1):28-33. DOI:10.1159/000087242.; Kamineni P, Prakasa K, Hasan SP, et al. Cardiotoxicities of paclitaxel in African Americans. J Natl Med Assoc. 2003;95(10):977-81.; Lombardi D, Crivellari D, Scuderi C, et al. Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori. 2004;90(3):285-8.; Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr. 1993;(15):117-30.; Guglin M, Aljayeh M, Saiyad S, et al. Introducing a new entity: chemotherapy-induced arrhythmia. Europace. 2009;11(12):1579-86. DOI:10.1093/europace/eup300.; Moscetti L, Ramponi S, Maccaglia C, et al. Atrial fibrillation in a patient with non-small-cell carcinoma of the lung in the course of paclitaxel therapy. Clin Ter. 1998;149(5):377-9.; Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18(2):317-24. DOI:10.1200/JCO.2000.18.2.317.; Mego M, Reckova M, Obertova J, et al. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol. 2007;18(11):1906-7. DOI:10.1093/annonc/mdm489.; Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007;99(9):727-37. DOI:10.1093/jnci/djk154.; Olin RL, Desai SS, Fox K, Davidson R. Non-myopathic cardiac events in two patients treated with trastuzumab. Breast J. 2007;13(2):211-2. DOI:10.1111/j.1524-4741.2007.00408.x.; Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009;100(5):684-92. DOI:10.1038/sj.bjc.6604909.; Kupari M, Volin L, Suokas A, et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant. 1990;5(2):91-8.; Yang X, Li X, Yuan M, et al. Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms. Front Pharmacol. 2018;9:1058. DOI:10.3389/fphar.2018.01058.; Aziz SA, Tramboo NA, Mohi-ud-Din K, et al. Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. Clin Oncol (R Coll Radiol). 1998;10(6):377-8. DOI:10.1016/s0936-6555(98)80033-2.; Meydan N, Kundak I, Yavuzsen T, et al. Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol. 2005;35(5):265-70. DOI:10.1093/jjco/hyi071.; Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006;24(7):1072-8. DOI:10.1200/JCO.2004.00.1792.; Ifran A, Kaptan K, Beyan C. High-dose cyclophosphamide and MESNA infusion can cause acute atrial fibrillation. Am J Hematol. 2005;80(3):247. DOI:10.1002/ajh.20441.; Bischiniotis TS, Lafaras CT, Platogiannis DN, et al. Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade. Hellenic J Cardiol. 2005;46(5):324-9.; Eskilsson J, Albertsson M, Mercke C. Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Oncol. 1988;13(1):41-6. DOI:10.1016/0167-8140(88)90296-4.; Menard O, Martinet Y, Lamy P. Cisplatin-induced atrial fibrillation. J Clin Oncol. 1991;9(1):192-3. DOI:10.1200/JCO.1991.9.1.192.; Tomkowski WZ, Wiśniewska J, Szturmowicz M, et al. Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer. 2004;12(1):53-7. DOI:10.1007/s00520-003-0533-x.; Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138(2):405-11. DOI:10.1016/j.jtcvs.2009.02.046.; Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24(10):1561-7. DOI:10.1200/JCO.2005.04.6813.; Zellos L, Richards WG, Capalbo L, et al. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostinecytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009;137(2):453-8. DOI:10.1016/j.jtcvs.2008.07.055.; Patel AK, Skatrud JB, Thomsen JH. Cardiac Arrhythmias Due to Oral Aminophylline in Patients With Chronic Obstructive Pulmonary Disease. Chest. 1981;80(6):661-5. DOI:10.1378/chest.80. 6.661.; Varriale P, Ramaprasad S. Aminophylline Induced Atrial Fibrillation. Pacing Clin Electrophysiol. 1993;16(10):1953-5. DOI:10.1111/j.1540-8159.1993.tb00987.x.; Chazan R, Karwat K, Tyminska K, et al. Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction. Int J Clin Pharmacol Ther. 1995;33(3):170-5.; Henderson A, Wright DM, Pond SM. Management of Theophylline Overdose Patients in the Intensive Care Unit. Anaesth Intensive Care. 1992;20(1):56-62. DOI:10.1177/0310057X9202000111.; Okada S, Teramoto S, Matsuoka R. Recovery From Theophylline Toxicity by Continuous Hemodialysis With Filtratio. Ann Intern Med. 2000;133(11):922. DOI:10.7326/0003-4819-133-11-200012050-00024.; Poukkula A, Korhonen UR, Huikuri H, Linnaluoto M. Theophylline and Salbutamol in Combination in Patients With Obstructive Pulmonary Disease and Concurrent Heart Disease: Effect on Cardiac Arrhythmias. J Intern Med. 1989;226(4):229-34. DOI:10.1111/j.1365-2796.1989.tb01385.x.; Raoof S, Wollschlager C, Khan FA. Ciprofloxacin increases serum levels of theophylline. Am J Med. 1987;82(4A):115-8.; Holden R. Probable fatal interaction between ciprofloxacin and theophylline. BMJ. 1988;297(6659):1339. DOI:10.1136/bmj.297.6659.1339.; Richardson JP. Theophylline Toxicity Associated With the Administration of Ciprofloxacin in a Nursing Home Patient. J Am Geriatr Soc. 1990;38(3):236-8. DOI:10.1111/j.1532-5415.1990.tb03497.x.; O' Driscoll BR. Supraventricular tachycardia caused by nebulized ipratropium bromide. Thorax. 1989;44(4):312. DOI:10.1136/thx.44.4.312.; Daubert GP, Mabasa VH, Leung VW, Aaron C. Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation. J Med Toxicol. 2007;3(2):56-60. DOI:10.1007/BF03160909.; MacMahon JR. Atrial fibrillation and sympathomimetics (letter). J Pediatr. 1974;84(4):613. DOI:10.1016/s0022-3476(74)80701-8.; Patane S, Marte F, La Rosa FC, La Rocca R. Atrial fibrillation associated with chocolate intake abuse and chronic salbutamol inhalation abuse. Int J Cardiol. 2010;145(2):e74-6. DOI:10.1016/j.ijcard.2008.12.159.; Hanrahan JP, Grogan DR, Baumgartner RA, et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore). 2008;87(6):319-28. DOI:10.1097/MD.0b013e31818fcc02.; Michele J, Stephan FL, Wentworth C 3rd, et al. Comparative Safety of Long-Acting Inhaled Bronchodilators: A Cohort Study Using the UK THIN Primary Care Database. Drug Saf. 2007;30(12):1151-60. DOI:10.2165/00002018-200730120-00007.; Veloso HH, de Paola AAV. Atrial fibrillation after vardenafil therapy. Emerg Med J. 2005;22(11):823. DOI:10.1136/emj.2004.015982.; Frederiksen MC, Toig RM, Depp R. III. Atrial fibrillation during hexoprenaline therapy for premature labor. Am J Obstet Gynecol. 1983;145(1):108-9. DOI:1016/0002-9378(83)90350-2.; Varkey S. Overdose of yohimbine. BMJ. 1992;304(6826):548. DOI:10.1136/bmj.304.6826.548-a.; Hayashi K, Minezaki KK, Narukawa M, et al. Atrial fibrillation and continuous 161. hypotension induced by sildenafil in an intermittent WPW syndrome patient. Jpn Heart J. 1999;40(6):827-30. DOI:10.1536/jhj.40.827.; Awan GM, Calderon E, Dawood G, Alpert MA. Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy. Am J Med Sci. 2000;320(1):69-71. DOI:10.1097/00000441-200007000-00011.; Cassinotti A, Massari A, Ferrara E., et al. New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. Eur J Clin Pharmacol. 2007;63(9):875-8. DOI:10.1007/s00228-007-0328-y.; Riccioni G, Bucciarelli V, Di Ilio E, et al. Recurrent atrial fibrillation in a patient with ulcerative colitis treated with azathioprine: case report and review of the literature. Int J Immunopathol Pharmacol. 2011;24(1):247-9. DOI:10.1177/039463201102400131.; Dodd HJ, Tatnall FM, Sarkany I. Fast atrial fibrillation induced by treatment of psoriasis with azathioprine. Br Med J (Clin Res Ed). 1985;291(6497):706. DOI:10.1136/bmj.291.6497.706.; Wooten MD, Reddy GV, Johnson RD. Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. Del Med J. 2000;72(12):517-19.; Paolicelli D, Manni A, Direnzo V, et al. Long-term Cardiac Safety and Tolerability of Fingolimod in Multiple Sclerosis: A Postmarketing Study. J Clin Pharmacol. 2015;55(10):1131-6. DOI:10.1002/jcph.519.; Rolf L, Muris A, Damoiseaux J, et al. Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment. Neurology 2014;82(11):1008-9. DOI:10.1212/WNL.0000000000000218.; Wallemacq PE, Lesne ML. Accidental massive IV administration of cyclosporine in man. Drug Intell Clin Pharm, 1985;19(1):29-30. DOI:10.1177/106002808501900106.; LoVecchio FA, Goltz HR. Atrial fibrillation following acute overdose with oral cyclosporine. Ann Pharmacother. 2000;34(3):405. DOI:10.1345/aph.19134.; Pratila MG, Pratilas V. Dysrhythmia occurring during epidural anesthesia with bupivacaine. The Mt Sinai J Med. 1982;49(2):130-2.; Heckbert S, Guo L, Steven RC, et al. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women. Arch Intern Med. 2008;168(8):826-31. DOI:10.1001/archinte.168.8.826.; Grosso A, Douglas I, Hingorani A. Oral Bisphosphonates and Risk of Atrial Fibrillation and Flutter in Women: A Self-Controlled Case-Series Safety Analysis. PLoS One. 2009;4(3):e4720. DOI:10.1371/journal.pone.0004720.; Herrera L, Leal I, Lapi F, et al. Risk of Atrial Fibrillation Among Bisphosphonate Users: A Multicenter, Population-Based, Italian Study. Osteoporosis Int. 2015;26(5):1499-506. DOI:10.1007/s00198-014-3020-y.; Black DM, Reiss TF, Nevitt MC, et al. Design of the Fracture Intervention Trial. Osteoporosis Int. 1993;3(3):S29-S39. DOI:10.1007/BF01623005.; Black DM, Delmas PD, Eastell R, et al. Once-yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007;356(18):1809-22. DOI:10.1056/NEJMoa067312.; Konsta M, Bournia VK, Dania V, Iliopoulos A. Atrial Fibrillation Following Intravenous Zolendronic Acid for Osteoporosis. J Clin Rheumatol. 2014;20(4):239-40. DOI:10.1097/RHU.0000000000000114.; Lau DH, Stiles MK, John B, et al. Atrial fibrillation and anabolic steroid abuse. Int J Cardiol. 2007;117(2):e86-7. DOI:10.1016/j.ijcard.2006.11.199.; Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med. 1999;17(5):851-7. DOI:10.1016/s0736-4679(99)00095-5.; Frost L, Vestergaard P. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr. 2005;81(3):578-82. DOI:10.1093/ajcn/81.3.578.; Choragudi NL, Aronow WS, DeLuca AJ. Nicotine gum-induced atrial fibrillation. Heart Dis. 2003;5(2):100-1. DOI:1010.1097/01.hdx.0000061700.11321.1a.; Stewart PM, Catterall JR. Chronic nicotine ingestion and atrial fibrillation. Br Heart J. 1985;54(2):222-3. DOI:10.1136/hrt.54.2.222.; Rigotti NA, Eagle KA. Atrial fibrillation while chewing nicotine gum. JAMA 1986;255(8):1018.; Craig TJ, Samuel LW, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-76. DOI:10.1016/j.jacc.2014.03.022.; Smeets JL, Allessie MA, Lammers WJ, et al. The Wavelength of the Cardiac Impulse and Reentrant Arrhythmias in Isolated Rabbit Atrium. The Role of Heart Rate, Autonomic Transmitters, Temperature, and Potassium. Circ Res. 1986;58(1):96-108. DOI:10.1161/01.res.58.1.96.; Rensma PL, Allessie MA, Lammers WJ, et al. Length of Excitation Wave and Susceptibility to Reentrant Atrial Arrhythmias in Normal Conscious Dogs. Circ Res. 1988;62(2):395-410. DOI:10.1161/01.res.62.2.395.; Wakili R, Voigt N, Kaab S, et al. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011;121(8):2955-68. DOI:10.1172/JCI46315.; Ogawa M, Zhou S, Tan AY, et al. Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure. J Am Coll Cardiol. 2007;50(4):335-43. DOI:10.1016/j.jacc.2007.03.045.; Chen PS, Douglas P. Zipes Lecture. Neural mechanisms of atrial fibrillation. Heart Rhythm. 2006;3(11):1373-7. DOI:10.1016/j.hrthm.2006.08.010.; Zhou S, Chang CM, Wu TJ, et al. Nonreentrant focal activations in pulmonary veins in canine model of sustained atrial fibrillation. Am J Physiol Heart Circ Physiol. 2002;283(3):H1244–H1252. DOI:10.1152/ajpheart.01109.2001.; Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale based combined treatments against cancer. Cell Death Differ. 2014;21(1):1525. DOI:10.1038/cdd.2013.67.; Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63(10):945-53. DOI:10.1016/j.jacc.2013.11.026.; Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1(1):62-73. DOI:10.1161/CIRCEP.107.754564.; Hove-Madsen L, Llach A, Bayes-Genis A, et al. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation. 2004;110(11):1358-63. DOI:10.1161/01.CIR.0000141296.59876.87.; Vest JA, Wehrens XH, Reiken SR, et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation. 2005;111(16):2025-32. DOI:10.1161/01.CIR.0000162461.67140.4C.; Chelu MG, Sarma S, Sood S, et al. Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin Invest. 2009;119(7):1940-51. DOI:10.1172/jci37059.; Neef S, Dybkova N, Sossalla S, et al. CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res. 2010;106(6): 1134-44. DOI:10.1161/CIRCRESAHA.109.203836.; Dobrev D, Voigt N, Wehrens X H. The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. Cardiovasc Res. 2011;89(4):734-43. DOI:10.1093/cvr/cvq324.; Voigt N, Heijman J, Wang Q, et al. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation. 2014;129(2):145-56. DOI:10.1161/CIRCULATIONAHA.113.006641.; Voigt N, Li N, Wang Q, et al. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation. 2012;125(17):2059-70. DOI:10.1161/CIRCULATIONAHA.111.067306.; Xing Y, Gao Y, Chen J, et al. Wenxin-Keli regulates the calcium/calmodulin-dependent protein kinase ii signal transduction pathway and inhibits cardiac arrhythmia in rats with myocardial infarction. Evid Based Complement Alternat Med. 2013;2013:464508. DOI:10.1155/2013/464508.; Yang X, Yu C, Li Y, et al. Effects of Wenxin Keli on cardiac hypertrophy and arrhythmia via regulation of the calcium/calmodulin dependent kinase ii signaling pathway. BioMed Res Int. 2017;2017:1569235. DOI:10.1155/2017/1569235.; Sag CM, Köhler AC, Anderson ME, et al. CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. J Mol Cell Cardiol. 2011;51(5):749-59. DOI:10.1016/j.yjmcc.2011.07.016.; Давтян К.В., Калемберг А.А., Царева Е.Н., и др. Роль воспалительной теории в патогенезе фибрилляции предсердий. Российский Кардиологический Журнал 2019;24(7):110-4. DOI:10.15829/1560-4071-2019-7-110-114.; Gedikli O, Dogan A, Altuntas I, et al. Inflammatory markers according to types of atrial fibrillation. Int J Cardiol. 2007;120(2):193-7. DOI:10.1016/j.ijcard.2006.09.015.; Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J. 2004;148(3):462-6. DOI:10.1016/j.ahj.2004.01.026.; Guzzetti S, Costantino G, Fundaro C. Systemic inflammation, atrial fibrillation, and cancer. Circulation. 2002;106(9):e40. DOI:10.1161/01.cir.0000028399.42411.13.; Wang ZX, Wang HQ, Cheng J, et al. Research progress on pathogenesis of atrial fibrillation. China Medical Herald. 2018;15;26-9.; Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14-25. DOI:10.1093/jnci/djp44.; Liu Y, Tan D, Shi L, et al. Blueberry anthocyaninsenriched extracts attenuate cyclophosphamide-induced cardiac injury. PLoS ONE. 2015 2;10(7):e0127813. DOI:10.1371/journal.pone.0127813.; Gu JF. The research progress on cardiac toxic mechanism of anthracyclines and prevention treatment measures. World Notes Antibiot. 2015;6:241-8. DOI:10.13461/j.cnki.wna.004903.; Yang X, Li Y, Li Y, et al. Oxidative stress-mediated atherosclerosis: mechanisms and therapies. Front Physiol. 2017;8:600. DOI:10.3389/fphys.2017.00600.; O’Neal WT, Lakoski SG, Qureshi W, et al. Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). Am J Cardiol. 2015;115(8):1090-4. DOI:10.1016/j.amjcard.2015.01.540.; Samman TA, Sandesara PB, Hayek SS, et al. Association between oxidative stress and atrial fibrillation. Heart Rhythm. 2017;14(12):1849-55. DOI:10.1016/j.hrthm.2017.07.028.; Beck MA. Selenium and host defence towards viruses. Proc Nutr Soc. 1999;58(3):707-11. DOI:10.1017/s0029665199000920.; Ozaki M, Deshpande SS, Angkeow P, et al. Inhibition of the Rac1 GTPase protects against nonlethal ischemia/reperfusion-induced necrosis and apoptosis in vivo. FASEB J. 2000;14(2):418-29. DOI:10.1096/fasebj.14.2.418.; Keefe DL Anthracyciine-Induced cardiomyopathy. Seminars in oncology 2001;28(4 suppl 12):2-7. DOI:10.1053/sonc.2001.26431.; Gen W, Tani M, Takeshita J, et al. Mechanisms of Ca2+ overioad induced by extracellular H2O2 in quiescent isoiated rat cardiomyocytes. Basic Res Cardiol. 2001;96(6):623-9. DOI:10.1007/s003950170014.; Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142(15):e214-e233. DOI:10.1161/CIR.0000000000000905.; Breeden CC, Safirstein BH. Spacer-induced Atrial Fibrillation. N J Med. 1990;87(2):113-4.; Сычев Д.А., Остроумова О.Д., Переверзев А.П., и др. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека. 2020;27(6):113-26. DOI:10.18565/pharmateca.2020.6.113-126.; Phillips BG, Gandhi AJ, Sanoski CA, et al. Comparison of Intravenous Diltiazem and Verapamil for the Acute Treatment of Atrial Fibrillation and Atrial Flutter. Pharmacotherapy. 1997;17(6):1238-45.; Minton NA, Henry JA. Treatment of Theophylline Overdose. Am J Emerg Med. 1996;14(6):606-12. DOI:10.1016/S0735-6757(96)90111-4.; Lancellotti P, Suter TM, López-Fernández T, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J. 2019;40(22):1756-63. DOI:10.1093/eurheartj/ehy453.; Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676. DOI:10.1093/europace/euab065.; Sychev D, Mirzaev K, Cherniaeva M, et al. Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. Drug Metab Pers Ther. 2020;35(3). DOI:10.1515/dmpt-2020-0127.; https://www.rpcardio.com/jour/article/view/2636

Availability: https://www.rpcardio.com/jour/article/view/2636
https://doi.org/10.20996/1819-6446-2021-12-11

Non-antibacterial methods for the prevention and treatment of recurrent lower urinary tract infections ; Неантибактериальные методы профилактики и лечения рецидивирующих инфекций нижних мочевых путей

Authors: N. D. Kubin, O. V. Volkova, D. D. Shkarupa, Н. Д. Кубин, О. В. Волкова, Д. Д. Шкарупа

Source: Urology Herald; Том 9, № 3 (2021); 92-106 ; Вестник урологии; Том 9, № 3 (2021); 92-106 ; 2308-6424 ; 10.21886/2308-6424-2021-9-3

Subject Terms: фитотерапия, cystitis, non-antibacterial treatment, d-mannose, estrogens, nonsteroidal anti-inflammatory drugs, probiotics, glycosaminoglycans, immunostimulants, herbal medicine, цистит, неантибактериальное лечение, d-манноза, эстрогены, нестеройдные противовоспалительные средства, пробиотики, гликозаминогликаны, иммуностимуляторы

File Description: application/pdf

Relation: https://www.urovest.ru/jour/article/view/477/344; Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001;183 Suppl 1:S1- 4. DOI:10.1086/318850; Rafalskiy V, Khodnevich L. Prevalence and risk factors of uncomplicated uti: multicentre study sonar. Eur Urol Suppl. 2008;7(3):267. DOI:10.1016/s1569-9056(08)60781-2; Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Am J Med. 2002;113(1 SUPPL. 1):5-13. DOI:10.1016/S0002-9343(02)01054-9; Кульчавеня Е.В., Шевченко С.Ю., Чередниченко А.Г. Диагностика и лечение цистита: вопросов больше, чем ответов? Урология, 2016;5:37-42. eLIBRARY ID: 27390794; Flower A, Wang LQ, Lewith G, Liu JP, Li Q. Chinese herbal medicine for treating recurrent urinary tract infections in women. Cochrane Database Syst Rev. 2015;2015(6):CD010446. DOI:10.1002/14651858.CD010446.pub2; Christiaens TCM, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer JM. Randomised Controlled Trial of Nitro-Furantoin versus Placebo in the Treatment of Uncomplicated Urinary Tract Infection in Adult Women. 2002.; Ostrovsky DA, Ehrlich A. Canephron® N (BNO 1045) may be Non-inferior to Single-dose Fosfomycin in Reducing the Need for Additional Antibiotics to Treat Women with Presumptive Uncomplicated Urinary Tract Infections. Explore (NY). 2019;15(2):165-7. DOI:10.1016/j.explore.2018.12.008; Howell AB. Bioactive compounds in cranberries and their role in prevention of urinary tract infections. Mol Nutr Food Res. 2007;51(6):732-7. DOI:10.1002/mnfr.200700038; Avorn J, Monane M, Gurwitz JH, Glynn RJ, Choodnovskiy I, Lipsitz LA. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA. 1994;271(10):751-4. DOI:10.1001/jama.1994.03510340041031; Howell AB, Botto H, Combescure C, Blanc-Potard AB, Gausa L, Matsumoto T, Tenke P, Sotto A, Lavigne JP. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect Dis. 2010;10:94. DOI:10.1186/1471-2334-10-94; Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10(10):CD001321. DOI:10.1002/14651858.CD001321.pub5; Luís Â, Domingues F, Pereira L. Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections? A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Clinical Trials. J Urol. 2017;198(3):614-21. DOI:10.1016/j.juro.2017.03.078; McMurdo ME, Argo I, Phillips G, Daly F, Davey P. Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women. J Antimicrob Chemother. 2009;63(2):389-95. DOI:10.1093/jac/dkn489; Schaeffer AJ, Chmiel JS, Duncan JL, Falkowski WS. Mannosesensitive adherence of Escherichia coli to epithelial cells from women with recurrent urinary tract infections. J Urol. 1984;131(5):906-10. DOI:10.1016/s0022-5347(17)50706-5; Spaulding CN, Klein RD, Ruer S, Kau AL, Schreiber HL, Cusumano ZT, Dodson KW, Pinkner JS, Fremont DH, Janetka JW, Remaut H, Gordon JI, Hultgren SJ. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature. 2017;546(7659):528-32. DOI:10.1038/nature22972; Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32(1):79-84. DOI:10.1007/s00345-013-1091-6; Vicariotto F. Effectiveness of an association of a cranberry dry extract, D-mannose, and the two microorganisms Lactobacillus plantarum LP01 and Lactobacillus paracasei LPC09 in women affected by cystitis: a pilot study. J Clin Gastroenterol. 2014;48 Suppl 1:S96-101. DOI:10.1097/MCG.0000000000000224; Palleschi G, Carbone A, Zanello PP, Mele R, Leto A, Fuschi A, Al Salhi Y, Velotti G, Al Rawashdah S, Coppola G, Maurizi A, Maruccia S, Pastore AL. Prospective study to compare antibiosis versus the association of N-acetylcysteine, D-mannose and Morinda citrifolia fruit extract in preventing urinary tract infections in patients submitted to urodynamic investigation. Arch Ital Urol Androl. 2017;89(1):45-50. DOI:10.4081/aiua.2017.1.45; Lenger SM, Bradley MS, Thomas DA, Bertolet MH, Lowder JL, Sutcliffe S. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;223(2):265.e1-265.e13. DOI:10.1016/j.ajog.2020.05.048; Lipovac M, Kurz C, Reithmayr F, Verhoeven HC, Huber JC, Imhof M. Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynaecol Obstet. 2007;96(3):192-5. DOI:10.1016/j.ijgo.2006.11.025; Nishimura M, Yan W, Mukudai Y, Nakamura S, Nakamasu K, Kawata M, Kawamoto T, Noshiro M, Hamada T, Kato Y. Role of chondroitin sulfate-hyaluronan interactions in the viscoelastic properties of extracellular matrices and fluids. Biochim Biophys Acta. 1998;1380(1):1-9. DOI:10.1016/s0304-4165(97)00119-0; Torella M, Schettino MT, Salvatore S, Serati M, De Franciscis P, Colacurci N. Intravesical therapy in recurrent cystitis: a multi-center experience. J Infect Chemother. 2013;19(5):920-5. DOI:10.1007/s10156-013-0609-6; Goddard JC, Janssen DAW. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J. 2018;29(7):933-42. DOI:10.1007/s00192-017-3508-z; Кудрявцев Ю.В., Кирпатовский В.И., Перепанова Т.С., Хазан П.Л. Применение стабилизатора гликозаминогликанов – гиалуроната цинка, при экспериментальном моделировании острого бактериального и интерстициального цистита. Экспериментальная и клиническая урология. 2011;(1):39-44. eLIBRARY ID: 17331832; De Vita D, Antell H, Giordano S. Effectiveness of intravesical hyaluronic acid with or without chondroitin sulfate for recurrent bacterial cystitis in adult women: a meta-analysis. Int Urogynecol J. 2013;24(4):545-52. DOI:10.1007/s00192-012-1957-y; Lee BS, Bhuta T, Simpson JM, Craig JC. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10(10):CD003265. DOI:10.1002/14651858.CD003265.pub3; Forbes R, Ali A, Abouhajar A, Brennand C, Brown H, Carnell S, Chadwick T, Eardley I, Lecouturier J, Mossop H, Pearce I, Pickard R, Thiruchelvam N, Walton K, Wilkinson J, Harding C. ALternatives To prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women (ALTAR): study protocol for a multicentre, pragmatic, patient-randomised, non-inferiority trial. Trials. 2018;19(1):616. DOI:10.1186/s13063-018-2998-4; Hannan TJ, Roberts PL, Riehl TE, van der Post S, Binkley JM, Schwartz DJ, Miyoshi H, Mack M, Schwendener RA, Hooton TM, Stappenbeck TS, Hansson GC, Stenson WF, Colonna M, Stapleton AE, Hultgren SJ. Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis. EBioMedicine. 2014;1(1):46-57. DOI:10.1016/j.ebiom.2014.10.011; Gágyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: Randomised controlled trial. BMJ. 2015;351. DOI:10.1136/bmj.h6544; Kalle AM, Rizvi A. Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor. Antimicrob Agents Chemother. 2011;55(1):439-42. DOI:10.1128/AAC.00735-10; Schmidhammer S, Ramoner R, Höltl L, Bartsch G, Thurnher M, Zelle-Rieser C. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology. 2002;60(3):521-6. DOI:10.1016/s0090-4295(02)01767-3; Волкова Е.В., Хоменков В.Г., Ахматова Э.А., Чалая Е.Л., Сорокина Е.В., Ахматова Н.К., Перепанова Т.С. Цитокиновый статус больных с рецидивирующей инфекцией нижних мочевых путей. Экспериментальная и клиническая урология. 2016;1:58-65. eLIBRARY ID: 29899520; Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013;190(6):1981-9. DOI:10.1016/j.juro.2013.04.142; Naber KG, Cho YH, Matsumoto T, Schaeffer AJ. Immunoactive prophylaxis of recurrent urinary tract infections: a metaanalysis. Int J Antimicrob Agents. 2009;33(2):111-9. DOI:10.1016/j.ijantimicag.2008.08.011; Wagenlehner FM, Ballarini S, Pilatz A, Weidner W, Lehr L, Naber KG. A Randomized, Double-Blind, Parallel-Group, Multicenter Clinical Study of Escherichia coli-Lyophilized Lysate for the Prophylaxis of Recurrent Uncomplicated Urinary Tract Infections. Urol Int. 2015;95(2):167-76. DOI:10.1159/000371894; Naber KG, Bonkat G, Wagenlehner FME. The EAU and AUA/ CUA/SUFU Guidelines on Recurrent Urinary Tract Infections: What is the Difference? Eur Urol. 2020;78(5):645-6. DOI:10.1016/j.eururo.2020.06.032; Yang B, Foley S. First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune®. BJU Int. 2018;121(2):289-92. DOI:10.1111/bju.14067; Lorenzo-Gómez MF, Padilla-Fernández B, García-Criado FJ, Mirón-Canelo JA, Gil-Vicente A, Nieto-Huertos A, SilvaAbuin JM. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int Urogynecol J. 2013;24(1):127-34. DOI:10.1007/s00192-012-1853-5; Aziminia N, Hadjipavlou M, Philippou Y, Pandian SS, Malde S, Hammadeh MY. Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int. 2019;123(5):753-68. DOI:10.1111/bju.14606; Prattley S, Geraghty R, Moore M, Somani BK. Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review. Eur Urol Focus. 2020;6(3):593-604. DOI:10.1016/j.euf.2019.11.002; Lüthje P, Lindén Hirschberg A, Brauner A. Estrogenic action on innate defense mechanisms in the urinary tract. Maturitas. 2014;77(1):32-6. DOI:10.1016/j.maturitas.2013.10.018; Raz R, Stamm WE. A Controlled Trial of Intravaginal Estriol in Postmenopausal Women with Recurrent Urinary Tract Infections. N Engl J Med. 1993;329(11):753-6. DOI:10.1056/nejm199309093291102; Raz R, Colodner R, Rohana Y, Battino S, Rottensterich E, Wasser I, Stamm W. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. Clin Infect Dis. 2003;36(11):1362- 8. DOI:10.1086/374341; Xu R, Wu Y, Hu Y. [Prevention and treatment of recurrent urinary system infection with estrogen cream in postmenopausal women]. Zhonghua Fu Chan Ke Za Zhi. 2001;36(9):531-3. (In Chinese). PMID: 11769665; Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;(2):CD005131. DOI:10.1002/14651858.CD005131.pub2; Chen YC, Chang CC, Chiu THT, Lin MN, Lin CL. The risk of urinary tract infection in vegetarians and non-vegetarians: a prospective study. Sci Rep. 2020;10(1). DOI:10.1038/s41598-020-58006-6; Wilson JD. Bacterial vaginosis: going full circle? Sex Transm Infect. 2017;93(3):220. DOI:10.1136/sextrans-2016-053014; Gupta K, Stapleton AE, Hooton TM, Roberts PL, Fennell CL, Stamm WE. Inverse association of H2O2-producing lactobacilli and vaginal Escherichia coli colonization in women with recurrent urinary tract infections. J Infect Dis. 1998;178(2):446-50. DOI:10.1086/515635; Mezzasalma V, Manfrini E, Ferri E, Boccarusso M, Di Gennaro P, Schiano I, Michelotti A, Labra M. Orally administered multispecies probiotic formulations to prevent uro-genital infections: a randomized placebo-controlled pilot study. Arch Gynecol Obstet. 2017;295(1):163-72. DOI:10.1007/s00404-016-4235-2; Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, Bruce AW. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol. 2003;35(2):131-4. DOI:10.1016/S0928-8244(02)00465-0; Colodner R, Edelstein H, Chazan B, Raz R. Vaginal colonization by orally administered Lactobacillus rhamnosus GG. Isr Med Assoc J. 2003;5(11):767-9. PMID: 14650098; Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ. 2001;322(7302):1571. DOI:10.1136/bmj.322.7302.1571; Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev. 2015;(12):CD008772. DOI:10.1002/14651858.CD008772.pub2; Ng QX, Peters C, Venkatanarayanan N, Goh YY, Ho CYX, Yeo WS. Use of Lactobacillus spp. to prevent recurrent urinary tract infections in females. Med Hypotheses. 2018;114:49- 54. DOI:10.1016/j.mehy.2018.03.001; Kim HY, Lee SJ, Lee DS, Yoo JM, Choe HS. Microbiological Characteristics of Unresolved Acute Uncomplicated Cystitis. Microb Drug Resist. 2016;22(5):387-91. DOI:10.1089/mdr.2015.0241; Paalanne N, Husso A, Salo J, Pieviläinen O, Tejesvi MV, Koivusaari P, Pirttilä AM, Pokka T, Mattila S, Jyrkäs J, Turpeinen A, Uhari M, Renko M, Tapiainen T. Intestinal microbiome as a risk factor for urinary tract infections in children. Eur J Clin Microbiol Infect Dis. 2018;37(10):1881- 91. DOI:10.1007/s10096-018-3322-7; Magruder M, Sholi AN, Gong C, Zhang L, Edusei E, Huang J, Albakry S, Satlin MJ, Westblade LF, Crawford C, Dadhania DM, Lubetzky M, Taur Y, Littman E, Ling L, Burnham P, De Vlaminck I, Pamer E, Suthanthiran M, Lee JR. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat Commun. 2019;10(1):5521. DOI:10.1038/s41467-019-13467-w; Hocquart M, Pham T, Kuete E, Tomei E, Lagier JC, Raoult D. Successful Fecal Microbiota Transplantation in a Patient Suffering From Irritable Bowel Syndrome and Recurrent Urinary Tract Infections. Open Forum Infect Dis. 2019;6(10):ofz398. DOI:10.1093/ofid/ofz398; Tariq R, Pardi DS, Tosh PK, Walker RC, Razonable RR, Khanna S. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection Reduces Recurrent Urinary Tract Infection Frequency. Clin Infect Dis. 2017;65(10):1745- 7. DOI:10.1093/cid/cix618; Yoon BI, Kim SW, Ha US, Sohn DW, Cho YH. Risk factors for recurrent cystitis following acute cystitis in female patients. J Infect Chemother. 2013;19(4):727-31. DOI:10.1007/s10156-013-0556-2; Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. J Infect Dis. 2000;182(4):1177-82. DOI:10.1086/315827; Tomas ME, Getman D, Donskey CJ, Hecker MT. Overdiagnosis of Urinary Tract Infection and Underdiagnosis of Sexually Transmitted Infection in Adult Women Presenting to an Emergency Department. J Clin Microbiol. 2015;53(8):2686- 92. DOI:10.1128/JCM.00670-15; Кульчавеня ЕВ, Шевченко СЮ. Особенности лечения больных посткоитальным циститом (предварительные результаты). Медицина и образование в Сибири. 2015;2:23. eLIBRARY ID: 26027161; Foxman B, Frerichs RR. Epidemiology of urinary tract infection: II. Diet, clothing, and urination habits. Am J Public Health. 1985;75(11):1314-7. DOI:10.2105/ajph.75.11.1314; Nseir W, Taha M, Nemarny H, Mograbi J. The association between serum levels of vitamin D and recurrent urinary tract infections in premenopausal women. Int J Infect Dis. 2013;17(12):e1121-4. DOI:10.1016/j.ijid.2013.06.007; Arnljots R, Snaebjörnsson Arnljots E, Thorn J, Elm M, Moore M, Sundvall PD. Bacteriuria and vitamin D deficiency: a cross sectional study of 385 nursing home residents. BMC Geriatr. 2019;19(1):381. DOI:10.1186/s12877-019-1400-z; Hooton TM, Vecchio M, Iroz A, Tack I, Dornic Q, Seksek I, Lotan Y. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(11):1509-15. DOI:10.1001/jamainternmed.2018.4204; Hunt JC, Waller G. Psychological factors in recurrent uncomplicated urinary tract infection. Br J Urol. 1992;69(5):460-4. DOI:10.1111/j.1464-410x.1992.tb15588.x; Cai T, Mazzoli S, Migno S, Malossini G, Lanzafame P, Mereu L, Tateo S, Wagenlehner FM, Pickard RS, Bartoletti R. Development and validation of a nomogram predicting recurrence risk in women with symptomatic urinary tract infection. Int J Urol. 2014;21(9):929-34. DOI:10.1111/iju.12453; https://www.urovest.ru/jour/article/view/477

Availability: https://www.urovest.ru/jour/article/view/477
https://doi.org/10.21886/2308-6424-2021-9-3-92-106

The analysis of prolonged-release drugs at the Ukrainian pharmaceutical market ; Исследование лекарственных препаратов пролонгированного действия на фармацевтическом рынке Украины ; Дослідження лікарських препаратів пролонгованої дії на фармацевтичному ринку України

Authors: Tarapon, K. V., Tryhubchak, O. V.

Source: Social Pharmacy in Health Care; Vol. 7 No. 3 (2021); 64-72 ; Социальная фармация в здравоохранении; Том 7 № 3 (2021); 64-72 ; Соціальна фармація в охороні здоров’я; Том 7 № 3 (2021); 64-72 ; 2518-1564 ; 2413-6085

Subject Terms: пролонговані лiкарськi засоби, маркетинговий аналіз, таблетки, нестероїдні протизапальні засоби, пролонгированные лекарственные средства, маркетинговый анализ, нестероидные противовоспалительные средства, prolonged-release drugs, marketing analysis, tablets, nonsteroidal anti-inflammatory drugs

File Description: application/pdf

Relation: http://sphhcj.nuph.edu.ua/article/view/232445/238735; http://sphhcj.nuph.edu.ua/article/view/232445

Availability: http://sphhcj.nuph.edu.ua/article/view/232445
https://doi.org/10.24959/sphhcj.21.228

Suprapatellar bursitis in a newborn ; Супрапателлярный бурсит у новорожденного

Authors: Erenkov I.O., Denisov I.S., Zarubina S.A.

Source: Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care; Vol 10, No 2 (2020); 199-202 ; Российский вестник детской хирургии, анестезиологии и реаниматологии; Vol 10, No 2 (2020); 199-202 ; 2587-6554 ; 2219-4061 ; 10.17816/psaic.20202

Subject Terms: bursitis, suprapatellar bursitis, infant, newborn, bursa synovial, case report, NSAIDs, inflammation, бурсит, супрапателлярный бурсит, новорожденный, неонатальный период, клинический случай, нестероидные противовоспалительные средства, НПВС, воспаление

File Description: application/pdf

Relation: https://rps-journal.ru/jour/article/view/644/pdf; https://rps-journal.ru/jour/article/downloadSuppFile/644/274; https://rps-journal.ru/jour/article/downloadSuppFile/644/275

Availability: https://rps-journal.ru/jour/article/view/644
https://doi.org/10.17816/psaic644